Official source · cited records
PubMed, page 4
2,673 public records from PubMed that PeptideScanner profiles or records cite, newest check first. Inclusion is not a source rating, endorsement, or claim of comprehensive monitoring.
Page 4 of 6
Official source · 2,673 cited records
- Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs. · retained source version 1:2017-11-16:current:99a4fbd8bc8711399024168d5fa7fbf10360fbf06bddff99eb54028943c497cf ↗Source checked August 13, 2026
- Content of DSIP, enkephalins and ACTH in some tissues of active and hibernating ground squirrels (Citellus suslicus). · retained source version 1:2020-08-25:current:f478bad5a63952ad0f1f796b2ac28f29146a02fd531e71b7782a4b1ccf052536 ↗Source checked August 13, 2026
- Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study. · retained source version 1:2026-01-28:current:f23ada615c8852418e57fcd9370a05c6c42481ce21261cf8cbd95b4443e36e4c ↗Source checked August 13, 2026
- Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review. · retained source version 1:2026-07-06:current:5f567d3e452268241bfe8b38e9cb67d478ecfc199e088ed494e40b8723452f3b ↗Source checked August 13, 2026
- Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide. · retained source version 1:2026-06-26:current:ac31cc7ff175cdb4039cbce8d233a7f5b3390d9c9f6c86ae33ccdf3240762921 ↗Source checked August 13, 2026
- Could MOTS-c Levels in Children with Type 1 Diabetes Mellitus Be an Indicator for Early Diabetic Kidney Disease? · retained source version 1:2025-05-31:current:3fffcaca15b62c25cc150a3e714d7f1e4036ad6176e5f8a9b3e3afc17af59107 ↗Source checked August 13, 2026
- Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus. · retained source version 1:2026-06-01:current:f95fdb4a332ee95ea94f2c23147f3f1f7d79a65c8f745764c6dcc3ce021a9bb3 ↗Source checked August 13, 2026
- Cyclophosphamide, cisplatin, and leuprolide acetate in patients with debulked stage III or IV ovarian carcinoma. · retained source version 1:2013-11-21:current:106e08f55429b6e17db7a37aa400329bf9ea2a63b7acbe9451338a7ee6a76021 ↗Source checked August 13, 2026
- Degradation of the ACTH(4-10) analog Semax in the presence of rat basal forebrain cell cultures and plasma membranes. · retained source version 1:2016-11-24:current:ed65b155bed12248bfdc90444f462fbfbe1ce0e2c0921009cc315273ff86f44b ↗Source checked August 13, 2026
- Delivery of ziconotide to cerebrospinal fluid via intranasal pathway for the treatment of chronic pain. · retained source version 1:2018-11-13:current:e38554f2a45bcc25e071d89dec2071348e5d222085f9c974439faae3005e9c28 ↗Source checked August 13, 2026
- Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications. · retained source version 1:2026-08-13:current:41bdad7796714760059177aeeebb9c4217b2973c075002cc8d757619c91b8b6e ↗Source checked August 13, 2026
- Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. · retained source version 1:2019-12-10:current:cae18ed17e9fa65452cb5e0d6df3552f03fe3164cb3019ec8dfa73ed728b07ee ↗Source checked August 13, 2026
- Detection of glucagon in urine by radioimmunoassay studies in normal and diabetic subjects. · retained source version 1:2004-11-17:current:61f332271ff414d40ba81e126bab3d71df03b9510a44230e241279bf64e59fac ↗Source checked August 13, 2026
- Development and validation of a new robust RP-HPLC method for simultaneous quantitation of insulin and pramlintide in non-invasive and smart glucose-responsive microparticles. · retained source version 1:2023-02-02:current:12ccc3e135ab9bea63eacb3ee4426d7a74921c641371ccf2c4c0f2254ada9995 ↗Source checked August 13, 2026
- Development and Validation of a Stability-Indicating RS HPLC Method for Leuprolide Acetate and Its Related Substances: Characterization of Degradation Products With LC-MS. · retained source version 1:2026-06-16:current:a72a3b0b23069215b1d687e2b1a48169ccd0b5b3821f5a89b1f18a666be6c3b3 ↗Source checked August 13, 2026
- Development of 1 month core-shell microspheres combination formulation containing teriparatide for osteoporosis treatment. · retained source version 1:2026-07-14:current:138dc8b36d3f34b7269528edda14cf873c453bd97108618ae60e24966dcbc49c ↗Source checked August 13, 2026
- Development of Dysplastic Nevi in a Child with LEPR Deficiency Treated with Setmelanotide. · retained source version 1:2025-08-21:current:5724bc41941d0ddd22f5c7894d5b28b236c9ec68e6c426fb413660086b4889d6 ↗Source checked August 13, 2026
- Development of zein-based nanoparticles for oral co-delivery of insulin and liraglutide and preliminary in vivo evaluation in Danio rerio. · retained source version 1:2026-07-15:current:62c411f64b93d33e42e64e175fc976474665bc983474a79f68d980e71ff05591 ↗Source checked August 13, 2026
- Differential penetration of DSIP peptides into rat brain. · retained source version 1:2019-07-12:current:0dfe5da32813f479dec08cd38645f74b2a77559e7dc79d4e6c2a6de96d034e16 ↗Source checked August 13, 2026
- Differential Role of Phosphorylation in Glucagon Family Receptor Signaling Revealed by Mass Spectrometry. · retained source version 1:2026-07-22:current:829d2f965ba462f3fec015e3dc6850d78f1a172abc9f735657b73294c58161f7 ↗Source checked August 13, 2026
- Discovery of Biased Dual-Agonists of Glucagon-Like Peptide 1 and Glucagon Receptors through Mutation of a Conserved Aspartate. · retained source version 1:2026-07-14:current:e1fa28e929e9fed3b2a5a655bec19cb27bf1e9ad9d5a84fbfd551aa58815a7ef ↗Source checked August 13, 2026
- Distribution and ontogeny of glucagon-like cells in the gastrointestinal tract of the cartilaginous fish Scyliorhinus stellaris (L.). · retained source version 1:2006-11-15:current:292334da21b889ee7c7dbb1467ae1a33fbbb0b191713c10bbc3f606186fb9c54 ↗Source checked August 13, 2026
- Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. · retained source version 1:2024-10-11:current:3cf98a28c98ddb06eebbdc8ddcdb3c686e702ba2ce248b8142c6ad542c11193b ↗Source checked August 13, 2026
- DSIP occurs in free form in mammalian plasma, human CSF and urine. · retained source version 1:2019-07-12:current:d02c6c428018dda3ef8c12e83795a85a172f14acc59169bd8196431eaec3ea0f ↗Source checked August 13, 2026
- DSIP--a tool for investigating the sleep onset mechanism: a review. · retained source version 1:2019-08-28:current:9e7807547f01a7a8b70cd459afc931dcedef5bc2ff93933d763db79e5c373cc9 ↗Source checked August 13, 2026
- DSIP-like immunoreactivity in the developing rat brain. · retained source version 1:2019-07-19:current:763f05e97159fb00e8c5f13f381b284ec83f019999d5042f9eb27db0b365fc8d ↗Source checked August 13, 2026
- DSIP-like material in brain parts of rats running a complex maze. · retained source version 1:2019-07-12:current:065eb591a6a283654b45919a77423f0845b71642f1c5fa1e47510451172e8ec6 ↗Source checked August 13, 2026
- DSIP/DSIP-P and circadian motor activity of rats under continuous light. · retained source version 1:2019-08-18:current:aa46e0837eaa6f7466cd7508dcbd98fa32163d9136f61726f14c8823dfadc416 ↗Source checked August 13, 2026
- Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus. · retained source version 1:2026-01-27:current:d3aed4b559553ed201245c97643feda3aa51ead80868a13c328b3360b527b4d7 ↗Source checked August 13, 2026
- Dulaglutide for erectile dysfunction in type 2 diabetes. · retained source version 1:2021-08-23:current:3aff3840d46361d94c820fa2de5bc3c8551642fb3daf46c859e1dcda9dfb5356 ↗Source checked August 13, 2026
- Dulaglutide for type 2 diabetes. · retained source version 1:2021-02-06:current:030c2700a1b0ee27b9f47b8ab46a80a1b75ea03424fa17ca65e8052db9a5aae4 ↗Source checked August 13, 2026
- Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: A case report. · retained source version 1:2020-05-11:current:62a9d2797c800b8c730729cad2690cdc8bde686d630597158feb56a17cd82cac ↗Source checked August 13, 2026
- Dysregulated glucagon signaling contributes to hypoglycemia after vertical sleeve gastrectomy in mice. · retained source version 1:2026-07-26:current:50837ea3dd380ca44eda42eef1b6c51f4e5d96d343d884df499ec7c0266ad00d ↗Source checked August 13, 2026
- Early cardiovascular-kidney-metabolic progression with tirzepatide: population definition and clinical interpretation. · retained source version 1:2026-06-06:current:3ec65c22ac3905250f69163294adeb6b784d67850a8073ac13b1ae0550327d40 ↗Source checked August 13, 2026
- Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study. · retained source version 1:2026-07-11:current:cb0ea16db9ea9913d75b921176b4278f35948394b5a8e16bbfe383c39dfb36f4 ↗Source checked August 13, 2026
- Economic Evaluation of Linaclotide for the Treatment of Adult Patients With Chronic Idiopathic Constipation in the United States. · retained source version 1:2026-01-27:current:1c6768fba05e07af95b8218e5e71712114656a19a9db4a623557f6075bd95041 ↗Source checked August 13, 2026
- Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States. · retained source version 1:2017-11-16:current:0f509b4c93cf79d8aea790d5ca3575de92b8b6f8b20039cdcfc86a23f1a14499 ↗Source checked August 13, 2026
- Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid. · retained source version 1:2025-07-28:current:067e0526282b47ad3def0faf0a9a390d8b25739774fa6b0553cfaac868cc63e5 ↗Source checked August 13, 2026
- Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report. · retained source version 1:2025-11-18:current:506865bd302d203673f4913d365ef6fe2adfbf85cbe80cf03e09b744cecfc857 ↗Source checked August 13, 2026
- Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval. · retained source version 1:2026-01-14:current:85a850a90afaf120fd282509822376f12f18ab63e6a893db5979cdc1097c8420 ↗Source checked August 13, 2026
- Elan: ziconotide review focused on off-label uses. · retained source version 1:2026-01-28:current:b76fdd674410678cf9cb522840a09fc48660f23f3243926a3785bae3c306501b ↗Source checked August 13, 2026
- Elucidation of the self-assembly pathway of lanreotide octapeptide into beta-sheet nanotubes: role of two stable intermediates. · retained source version 1:2016-11-25:current:204f8be609c71c6052ba5d93486cec2bb7cd2ca074b9c2883339a8234b584892 ↗Source checked August 13, 2026
- Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. · retained source version 1:2013-11-21:current:1c913976d8d6775d1d89d108b469f0b7ef9ebed0383ad400e0175f543122e510 ↗Source checked August 13, 2026
- Engineering a Glucose-Responsive Glucagon Prodrug Through Arginine-Phenylboronic Acid Pendant Modification. · retained source version 1:2026-08-13:current:13fdb21acb9236712917720dec562a0e909a8be568a09d8cd6b2f1f587a9bb26 ↗Source checked August 13, 2026
- Engineering of an Anti-Inflammatory Peptide Based on the Disulfide-Rich Linaclotide Scaffold. · retained source version 1:2020-09-30:current:bdb2b05dde80fc7eb312e3495e0021dfe70f02a71ba44f30a2ca86c85a2e1f3b ↗Source checked August 13, 2026
- Entry of DSIP peptides into dog CSF: role of physicochemical and pharmacokinetic parameters. · retained source version 1:2019-07-19:current:42047ccc9b79e87d7aef5c25fa3a678c52045b58f0bfb2c73eaf4ae33c282fd9 ↗Source checked August 13, 2026
- Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study. · retained source version 1:2021-02-23:current:5e4e601601ac9c46349bf3a26bf1f6e02bd15b3465ecec853a73edc7521e816a ↗Source checked August 13, 2026
- Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. · retained source version 1:2025-05-30:current:e20430e891ff10382af4da2df9e9bdfb7d1c82a7419ba40af212806934dc1d6e ↗Source checked August 13, 2026
- Evaluation of Serum Humanin and MOTS-c Peptide Levels in Patients with COVID-19 and Healthy Subjects. · retained source version 1:2026-01-27:current:b6cddb8e8fe90f57d3660981d5417f58437b1b3cdfae7ce0aa75a1c8a5b085fd ↗Source checked August 13, 2026
- Evaluation of somatostatin and the somatostatin analogue octreotide as therapeutic agents in gastrointestinal disorders. · retained source version 1:2013-11-21:current:4c9af057dc620930f4f4fe6bce7d8e318d0a9b83d96038363c40165822316198 ↗Source checked August 13, 2026
- Evaluation of vascular peroxidase 1, humanin, MOTS-c and miR-200c expression levels in untreated preeclampsia patients. · retained source version 1:2026-01-27:current:e44e5434fa978f28740a9dff7a18f685c3a9d62ceeca1fa4276fe5aeb9999843 ↗Source checked August 13, 2026
- Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. · retained source version 1:2026-01-28:current:ca85a2814dce3bd0a801a655ac3f1e3febee7257cafc2373dc517d339ff2cccb ↗Source checked August 13, 2026
- Exenatide and pancreatitis: an update. · retained source version 1:2026-01-28:current:54f5137810d1149c3619815d4ad583b046d3848b46685094e362eddad2122a16 ↗Source checked August 13, 2026
- Exenatide for type 2 diabetes. · retained source version 1:2026-01-28:current:b7ff3c5ddfdb7fccbcc4b7a8b8a04a5d019e7e020d953b3b76b81689fb7d98f2 ↗Source checked August 13, 2026
- Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. · retained source version 1:2026-01-28:current:13f91960a2bfc7ea6f36d68aeaef25cd1898c5b1913268f9ea1f3dee2accf023 ↗Source checked August 13, 2026
- Exenatide versus glibenclamide in patients with diabetes. · retained source version 1:2026-01-28:current:b9f4825ef2a47516b448fceca29401213d1106f4fe375ab337ad60677293d8e4 ↗Source checked August 13, 2026
- Exenatide: new drug. Type 2 diabetes for some overweight patients. · retained source version 1:2026-01-28:current:e3ed84d60ac24d613a41e78ba8cee2d1361360f65c1f3b4d7d95e1a6aa4d1300 ↗Source checked August 13, 2026
- Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c). · retained source version 1:2026-02-04:current:c1c965cee6783f0df070051c06a40e5705940271db46f31e4e38b1b27898acac ↗Source checked August 13, 2026
- Expanded-access use of elamipretide in a critically ill patient with Barth syndrome. · retained source version 1:2024-12-14:current:d054d25c2ef27ac3ecdfea92d93206bee8987c744ddb04cdd151bf6861e0706f ↗Source checked August 13, 2026
- Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report. · retained source version 1:2025-02-08:current:0e4a75526b6907a2c248ce693486c9a41703e57251d2f13a41f16706b5f65d87 ↗Source checked August 13, 2026
- Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens. · retained source version 1:2026-01-28:current:43ea9aa337d09491cbb0dfc2ecce0ce50228a7f93515d35fd46369af867726dd ↗Source checked August 13, 2026
- Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study. · retained source version 1:2026-06-23:current:e4a6cca587584fd8b898738be612b59523ff80703228ba0cb82d9f14b1027c56 ↗Source checked August 13, 2026
- Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. · retained source version 1:2026-01-28:current:5d562581ca9eab78233953d470dbfb092da71c9ba9f57f22f7ac561137ab867a ↗Source checked August 13, 2026
- Fear of hypoglycemia in parents of children with type 1 diabetes trained for intranasal glucagon use. · retained source version 1:2026-07-27:current:63874759153945c8e5c9d5422d4c80226b7fe55a503367887b4eb907c0238d7c ↗Source checked August 13, 2026
- Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. · retained source version 1:2019-08-23:current:607687c79aa16bae7bf246bc84dba98f95d382c8a232fc44243d5901e937da68 ↗Source checked August 13, 2026
- Fourier Transform Infrared Spectroscopic Characterization of Aortic Wall Remodeling by Stable Gastric Pentadecapeptide BPC 157 After Unilateral Adrenalectomy in Rats. · retained source version 1:2026-01-31:current:3d8e778d21551f7435a9d6d04b2ff7ec4af6ad3f0570231061a55537c6ad3bb5 ↗Source checked August 13, 2026
- From darkness to light: Case report on afamelanotide-treatment in a 9-year-old child with erythropoietic protoporphyria. · retained source version 1:2026-01-18:current:6d36ea5ea3000b5566b3cd7c47b4dcc0e76d40ac9ffdc26ed668f8090e154a84 ↗Source checked August 13, 2026
- GLP-1, GIP, and Glucagon Excursions During a Mixed Meal Tolerance Test in Young and Lean South Asians Versus Europids. · retained source version 1:2026-07-15:current:6e5838b9bdd7f43f2496aaf9da3a2a4c4d4473b955e0323a002e4185724eddb0 ↗Source checked August 13, 2026
- GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives. · retained source version 1:2026-05-15:current:8c651c83f6d4aaa37355c4997fdb7cfe04b16f75cc31c285049aa197191d917a ↗Source checked August 13, 2026
- Glucagon administration for the treatment of postoperative cholangitis after Kasai's operation--a preliminary report. · retained source version 1:2004-11-17:current:6ea7ddf4858b76947f702aa9fbb02a7388af1e872c76bc25dba7f0aaa6b10382 ↗Source checked August 13, 2026
- Glucagon and GLP-1 receptors: lessons from chimeric ligands and receptors. · retained source version 1:2005-11-17:current:d2ef57e3f28963b203aa2f371049e97f9498456ca391a8ec37eb7f7d99441bbd ↗Source checked August 13, 2026
- Glucagon and obesity. · retained source version 1:2004-11-17:current:877c8bfc6f610fad0bf609241711dc3d77a19d1a77394ce3bd6950306be69970 ↗Source checked August 13, 2026
- Glucagon and related peptides (an overview). · retained source version 1:2006-11-15:current:2ba79e357aba827862da43a5e84ddc9400dc4ce4f52aab5ed7e8e15cd9d355c1 ↗Source checked August 13, 2026
- Glucagon facilitates end-to-end pancreaticojejunostomy. · retained source version 1:2004-11-17:current:a8f7a28d817c1422cba8f148c3c17ef48ffbbb268b3d2b342fc1f8f69c6f54e4 ↗Source checked August 13, 2026
- Glucagon gene 3'-flanking sequences direct formation of proglucagon messenger RNA 3'-ends in islet and nonislet cells lines. · retained source version 1:2006-11-15:current:187a40d4dda353b5e77edc8ba5199d974d2812069ca9cb3d5835fda0e76bb22b ↗Source checked August 13, 2026
- Glucagon in the treatment of cardiogenic shock following acute myocardial infarction. · retained source version 1:2004-11-17:current:64f0fe08c66c3a02ffb4735622dc19002fa22e3c0c55919222877498cd7e3b71 ↗Source checked August 13, 2026
- Glucagon receptor gene mutation in essential hypertension. · retained source version 1:2004-11-17:current:84a748d076423ccb8d642aebd3a00edd7f07575ba89dbf90122268ffad1cf8c5 ↗Source checked August 13, 2026
- Glucagon treatment in NICTH. · retained source version 1:2004-11-17:current:a27c4b136bd5370d61108594fa4c9ec7eb6ec3069dffc136fd77acce4d85d704 ↗Source checked August 13, 2026
- Glucagon, glucagon-like peptide-1 and their receptors: an introduction. · retained source version 1:2005-11-17:current:836444cd7187cb368b7327dc13c0fac94637f8191b312ab63c55c67e18e7b526 ↗Source checked August 13, 2026
- Glucagon, physiological and pharmacological aspects. · retained source version 1:2004-11-17:current:825c14f953154f6005c2a2c7c26730491517911ef9825a16ef13ca62db4e8484 ↗Source checked August 13, 2026
- Glucagon: hormone or therapeutic agent? · retained source version 1:2004-11-17:current:6c5ce1d4a659c2e07cd7b2c8131c0d75a2bc5d83940296a026247cf754db176c ↗Source checked August 13, 2026
- Glutamine Metabolism Supports α cell Mass and Glucagon Secretion. · retained source version 1:2026-07-29:current:81347396802fb2a14de829ff4cffed6ee1f061c569aa0b865fdbc393ff402fa3 ↗Source checked August 13, 2026
- Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. · retained source version 1:2026-01-27:current:e6483945acbafb19aa5e8c24d72ca0995c20517316e4b93de46074aea7dc722a ↗Source checked August 13, 2026
- Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials. · retained source version 1:2022-07-22:current:7db9b1636c0bdfea988695e73f8b8cd10f53e725e0626e5fd1e7d100c47688f4 ↗Source checked August 13, 2026
- Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes. · retained source version 1:2026-07-05:current:721e704c2479a2ef8e4598406e370bca1bdc213d4d113f7be93155585fef2736 ↗Source checked August 13, 2026
- Health Care Resource Use and Costs Pre- and Post-Treatment Initiation With Linaclotide: Retrospective Analyses of a U.S. Insured Population. · retained source version 1:2026-01-27:current:29289767d64c091c0d5be19586103dc4b34608643fb9b8f2e8eb10e0d0e6f82c ↗Source checked August 13, 2026
- Human pheochromocytoma cells studied in culture contain large amounts of DSIP-like material. · retained source version 1:2019-08-18:current:981c607957ac3568e406df9ba8230644493295461d181f2a761980849edcecc7 ↗Source checked August 13, 2026
- Hyperglycemia and insulin resistance during glucagon infusion. · retained source version 1:2004-11-17:current:dcfd08f74148506aa3f133f460a9777b8640d0b081c5ab8f08ecb1f93357b56c ↗Source checked August 13, 2026
- Hypothesis: a role for glucagon as a mineralocorticoid antagonist during the first postnatal week. · retained source version 1:2004-11-17:current:e9155974c0cde930a1755c89b25cde2839ca4e0fa903707a86ce14d4bb11c7f6 ↗Source checked August 13, 2026
- Ibuprofen hepatic encephalopathy, hepatomegaly, gastric lesion and gastric pentadecapeptide BPC 157 in rats. · retained source version 1:2018-12-01:current:8950028bf2b8c7658f6215e80c51db01816a254a110b6ab6f05a9753a4f00500 ↗Source checked August 13, 2026
- Identification of insulin and glucagon genes in the finless porpoise and the developmental distribution of their producing endocrine cells. · retained source version 1:2026-07-16:current:450168f95836c7edd9c4b2b6f83c9190a65d662c248776b1ddf090b880821bb8 ↗Source checked August 13, 2026
- Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data. · retained source version 1:2026-01-27:current:15798e96daf651afc6e9ce13ad2e7b23506fdabcd9f6ecd7335627321a25386a ↗Source checked August 13, 2026
- Immunohistochemical distribution of DSIP immunoreactivity in the human hypothalamus during the first postnatal year. A preliminary report. · retained source version 1:2025-12-30:current:77d511dc225ea9c657349f30db48cf1972c987218e477f85208da9cd73a2bbda ↗Source checked August 13, 2026
- In Vitro and in Vivo Studies of pH-Sensitive GHK-Cu-Incorporated Polyaspartic and Polyacrylic Acid Superabsorbent Polymer. · retained source version 1:2023-10-20:current:e0a171b0fd907e25395dfd9338e6f72664af496592ee710b32f87240c6fd15e1 ↗Source checked August 13, 2026
- In vitro transdermal iontophoretic delivery of leuprolide under constant current application. · retained source version 1:2013-11-21:current:4fbed636b7192fd01e19aa649d4eaf6b591955dc123a067a659defa5839003ed ↗Source checked August 13, 2026
- In vivo dysregulation of insulin and glucagon secretion: Disturbed mitochonderial VDAC1 expression and localization in pancreatic β-cells convey global insulin secretory defects in diabetic GK rat. · retained source version 1:2026-07-11:current:d15e46a163496d7fb75ba362ecaad0f6882721ffaa56aaa9313fedd0ff9eb471 ↗Source checked August 13, 2026
- Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression. · retained source version 1:2026-07-18:current:8487f02e73170f1cb7089446390f7333b900b3796337b74a28372d5ad00e1722 ↗Source checked August 13, 2026
- Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand. · retained source version 1:2025-09-11:current:f5bf2127dcc555ad8e0ed58dd45a603534158f4cc97b6d306d6f7cc2312041d7 ↗Source checked August 13, 2026
- Inflammatory Cytokines Impair Glucagon Expression and Secretion in Pancreatic α-Cells. · retained source version 1:2026-07-26:current:772e89e13b0dae5aba127a46b3443897177bc08b5a87834ad261ea1e28a66147 ↗Source checked August 13, 2026
- Influence of ACTG4-7-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress. · retained source version 1:2018-03-19:current:484968c63b4ee640830ed0ca4c01e0f74555725cf2f7bcd24e7b993eefbe1317 ↗Source checked August 13, 2026
- Influence of pH and temperature on ziconotide stability in intrathecal analgesic admixtures in implantable pumps and syringes. · retained source version 1:2016-11-25:current:21b5d355edac7a60b4cd04387994813bb78cbf4eec669e8c9d4859a0f6c77ec2 ↗Source checked August 13, 2026
- Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students. · retained source version 1:2026-07-17:current:4b8a02c2889cbb274bf8c90830dddb2fed0a187490ab3d4db9ba42c4712f7d7c ↗Source checked August 13, 2026
- Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. · retained source version 1:2018-03-12:current:c9cdf57a5b6bd3ad40059382d556a26ed427133b6a67a8358edd55e1a5c25990 ↗Source checked August 13, 2026
- Initial experience with teriparatide in the United States. · retained source version 1:2013-11-21:current:85823488c3d427ea1f8fdda0e0e95ef35ff92f34f825bf7af62e27eba0e2bb22 ↗Source checked August 13, 2026
- Insulin degludec, Lixisenatide, and Patiromer sorbitex calcium. · retained source version 1:2026-01-27:current:2795fc8c5bfbb0eae47632e759de91744faf50a98c73dee7b744e54d38d86b9b ↗Source checked August 13, 2026
- Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. · retained source version 1:2026-01-27:current:d7247fdd4d57938d859f9e82d712bb1f0bc5b45402267f72631cdabf3db6ccb6 ↗Source checked August 13, 2026
- Intermittent treatment with elamipretide preserves exercise tolerance in aged female mice. · retained source version 1:2024-07-19:current:739c298e887e8b689a7e5ffcdd843d60a2a049d3c31a73107a78c1ad3116ede3 ↗Source checked August 13, 2026
- Interruption of glucagon signaling augments islet non-alpha cell proliferation in SLC7A2- and mTOR-dependent manners. · retained source version 1:2026-07-26:current:463dfd06aa397cf3a5db6056cc0ac88af007abe639c3df814a3ac48f09aa3751 ↗Source checked August 13, 2026
- Intervention of kidney and liver in glucagon catabolism and clearance from plasma. · retained source version 1:2004-11-17:current:051635a7117c19000aaddb5630b2f821a7801d5e4d6e2784de99a9c0f6bbd398 ↗Source checked August 13, 2026
- Intrathecal ziconotide for chronic pain. · retained source version 1:2026-01-28:current:f1871bcb0e07d0a00dd4ddfa73de2752be8d67021aa14cb4f60424e1aadff6db ↗Source checked August 13, 2026
- Intrathecal ziconotide for refractory chronic pain. · retained source version 1:2026-01-28:current:bcb767f52eab21a3b7329dcd76c535905351b7c5b0c7876ff1379d6005bf22e9 ↗Source checked August 13, 2026
- Intrathecal ziconotide for refractory pain. · retained source version 1:2026-01-28:current:156b340f32eedb7499eb1c197e50e6fa6e2e66637f91789a10c4c6bef5b659b6 ↗Source checked August 13, 2026
- Intravenous Glucagon Infusion in the Management of Hypoglycemia in Infants of Diabetic Mothers. · retained source version 1:2026-07-29:current:ac13daaf162b633e41085a623cd219bc4230d96115aa7344902cd2e2e0a53382 ↗Source checked August 13, 2026
- Isolation and identification of cyclic imide and deamidation products in heat stressed pramlintide injection drug product. · retained source version 1:2019-08-15:current:186cf3b01d6470977f3296bc7d7c0d10cc7cdbb448f04c7e65e0953335067b59 ↗Source checked August 13, 2026
- Isolation and identification of peptide degradation products of heat stressed pramlintide injection drug product. · retained source version 1:2019-08-18:current:e582d7aa50ad6702caeaad352eb1acb2395e892fa31409633d48698b2bfee325 ↗Source checked August 13, 2026
- Kinetics of pramlintide degradation in aqueous solution as a function of temperature and pH. · retained source version 1:2018-11-13:current:3a23aa177fe7f5524214364c0a9f87cfa8b5924b3ecd8661eba908c667ee2dde ↗Source checked August 13, 2026
- Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review. · retained source version 1:2016-11-24:current:25dcdf65b49d6893601141749ebc520a4e27307c2134c9abd8dd9fdd766da966 ↗Source checked August 13, 2026
- Lanreotide Autogel for persistent diabetic macular edema. · retained source version 1:2016-11-24:current:4f30b93e4eb99070c75306400e4ab9a950610c47a7e7be896061dbc9340657c2 ↗Source checked August 13, 2026
- Lanreotide in endothelial corneal inflammation. · retained source version 1:2026-03-25:current:a4ce3d1a2dbbb3d55f7922623629a063ca8894c59c34cdb0e9d9cc10d4ede6bd ↗Source checked August 13, 2026
- Laparoscopic resection for nonfunctioning small glucagon-producing tumor: report of a case and review of the literature. · retained source version 1:2004-11-17:current:41733f4b957357b1f9549680cd8be576fe6781a9b8ad7324db4b0d9987e906c6 ↗Source checked August 13, 2026
- Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients. · retained source version 1:2026-01-27:current:146cd4f420de4e52ab70787dcdace04b192b07a912e4bcda9231f7409a90a891 ↗Source checked August 13, 2026
- Latent phosphaturic mesenchymal tumor in left planta detected by [18F]F-AlF-NOTA-octreotide PET/CT. · retained source version 1:2026-07-11:current:5428cc059779304a786faaffce2924b184a8007137c6e89ea786626a883e04eb ↗Source checked August 13, 2026
- Leuprolide acetate for exhibitionism in Huntington's disease. · retained source version 1:2013-11-21:current:ba028385972de1eb6e7baebd606025ac1f421cbec7c1022c2e0af52ae7710c27 ↗Source checked August 13, 2026
- Leuprolide acetate treatment and myoma arterial size. · retained source version 1:2013-11-21:current:5bca8092c85f4bc5e85f14314de747b6c38779b7d8fd5b85f63c8c46b1a61842 ↗Source checked August 13, 2026
- Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. · retained source version 1:2013-11-21:current:9eb1b67ba63b550f7e014a6cd841af34edea8a04354ff7152853c478ae265f20 ↗Source checked August 13, 2026
- Leuprolide in the treatment of endometrial cancer. · retained source version 1:2013-11-21:current:8d5da1f0ef9da0108a0e3d229168a67c1a5779048a2a99c2260b4121dafe229a ↗Source checked August 13, 2026
- Linaclotide (Linzess) for constipation. · retained source version 1:2026-01-28:current:b553528b12e2f4d67c2d5ca784d7229b7f0f2a10724e95e6b2e5098904a451c7 ↗Source checked August 13, 2026
- Linaclotide as a Single Agent Bowel Preparation Regimen Before Colonoscopy. · retained source version 1:2025-09-11:current:4465a50ffe9ea288cd9d2dc35b6a736a8269da30c743ee7431d85909c6ac4eff ↗Source checked August 13, 2026
- Linaclotide for constipation-predominant IBS. · retained source version 1:2017-11-16:current:616667c7d06ee2b038eb278b4f4e928b825290e2099b5523b5c4f465a3045b0f ↗Source checked August 13, 2026
- Linaclotide for paediatric functional constipation. · retained source version 1:2025-06-05:current:5fbbd4f896df1cb21d7e837a8bea95fd2733a31367dc6c52c9be05671efd4933 ↗Source checked August 13, 2026
- Linaclotide for the treatment of chronic constipation. · retained source version 1:2019-03-18:current:0daca531a2782f955cd8beedbf98674eb121ba0eb85a5b35e297b542d270732c ↗Source checked August 13, 2026
- Linaclotide for the treatment of irritable bowel syndrome with constipation: is it time to reshuffle the deck? · retained source version 1:2018-12-02:current:ccaa6fe8e76d5d84797728a0f5998cef6feab9b5499d632a0345001a3a41112e ↗Source checked August 13, 2026
- Linaclotide in the treatment of patients with irritable bowel syndrome and constipation - analysis of an opportunity. · retained source version 1:2019-09-18:current:022cb5dad6179fb61acdf11c0e13a066135cd953906443075de52f235f884880 ↗Source checked August 13, 2026
- Linaclotide Use for the Treatment of Constipation and Gastrointestinal Symptoms in People With Cystic Fibrosis. · retained source version 1:2025-05-17:current:b7774b6bef333f096d128548eb1cf5e768dd609d4ee548b58ac5afea78bec7c8 ↗Source checked August 13, 2026
- Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application. · retained source version 1:2023-10-30:current:27e736ac92e95aa127dbc580e5340cd38ec82c76f68b6d0510aa95cf895a519f ↗Source checked August 13, 2026
- Liquid-Phase Total Synthesis of Plecanatide Aided by Diphenylphosphinyloxyl Diphenyl Ketone (DDK) Derivatives. · retained source version 1:2022-06-01:current:63570ccbc2614b1d65eb924947099ae47a32c835d736573e119e8d94dde3f6bf ↗Source checked August 13, 2026
- Liraglutide and systolic blood pressure. · retained source version 1:2026-07-07:current:36a1024df7911df730d9ba60c06db474cdbe8042b84931c61a16c137e3bc736c ↗Source checked August 13, 2026
- Liraglutide for idiopathic intracranial hypertension: a real-world propensity score-matched study. · retained source version 1:2026-06-30:current:83710087b0606d2a6b85176c170b86893e6f3504669105057bb5b2030b06c51b ↗Source checked August 13, 2026
- Liraglutide in combination with acitretin for severe recalcitrant psoriasis. · retained source version 1:2015-11-19:current:686be5368e1441205956250f65365f1eb55f525397adb11a92b3dd88508fcd6a ↗Source checked August 13, 2026
- Liraglutide in islet transplantation: from bench to bedside. · retained source version 1:2015-11-19:current:8142065e14ed33ad920e2ba824a59e23c12d17c933d9842d0de062fdada0050b ↗Source checked August 13, 2026
- Liraglutide therapy in Prader-Willi syndrome. · retained source version 1:2015-11-19:current:1232b8b426a0ff580b53335d34627df51c90550d0ef41cf194abe802491a2a83 ↗Source checked August 13, 2026
- Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome. · retained source version 1:2015-11-19:current:8d002470f2a8ce9e677961788c4b1e6340884c480f8b2ef6c6564e45ed2f6ffa ↗Source checked August 13, 2026
- Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus. · retained source version 1:2026-01-27:current:742d57981f1b6feb5dafabb69d9dcfd2255af5923c7508466b660678866d8e59 ↗Source checked August 13, 2026
- Lixisenatide for type 2 diabetes. · retained source version 1:2026-01-27:current:8c455dbe496c1c83123ead569de74aab5ccefde238443fd8fab14cb2fad228c8 ↗Source checked August 13, 2026
- Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. · retained source version 1:2025-01-03:current:65738778898d04972bd549b87072d4a04b947807f2ab38db6ca7f2b50926b399 ↗Source checked August 13, 2026
- Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. · retained source version 1:2025-01-03:current:7632e611d7c2dfdcfa48f51bda442a225451fb55639c70298780039f8030a8ca ↗Source checked August 13, 2026
- Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. · retained source version 1:2025-01-03:current:d47f0ab7f8255c56112d27b8a878950727a863add0f76bce92c171584f9e8b9c ↗Source checked August 13, 2026
- Lixisenatide versus insulin glulisine on top of insulin glargine in patients with type 2 diabetes mellitus: a cost-per-responder analysis in China. · retained source version 1:2026-01-27:current:c9b88cb4cccd34ff1e9f51bd0d89801f04163cfe5d267c0df257e280f5d42ea9 ↗Source checked August 13, 2026
- Lixisenatide. · retained source version 1:2024-05-23:current:b33587b3ae9322ae9bf90902711e5e4334d25a57e90020679fa48e4b65c8609c ↗Source checked August 13, 2026
- Long-acting lanreotide in adolescent girls with constitutional tall stature. · retained source version 1:2016-11-25:current:31d2a1eebfa99d0c52a97869cf6d8441594d3841074e3b5a9b720b54b7cc347b ↗Source checked August 13, 2026
- Long-lasting cytoprotection after pentadecapeptide BPC 157, ranitidine, sucralfate or cholestyramine application in reflux oesophagitis in rats. · retained source version 1:2019-11-03:current:78457f3093b16b358be3419640877fa1e102c6a70237e5ecf09418c5d557fadc ↗Source checked August 13, 2026
- Long-term treatment with linaclotide of intestinal pseudo-obstruction secondary to Ehlers-Danlos syndrome. · retained source version 1:2019-06-13:current:14e2cd939160719beb7a660d9f0c77e181cca2acc1b15db047be2e1ffef96943 ↗Source checked August 13, 2026
- Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist. · retained source version 1:2026-01-27:current:a29f3e7ebcd07af44da035dc31ca80409801728d1ead481051545d9669542a1f ↗Source checked August 13, 2026
- Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use. · retained source version 1:2026-07-17:current:b145ec90ac55ba79f43ae851c58bf98d5c04bfe5469d63514d9612c3a6656dba ↗Source checked August 13, 2026
- Managing advanced prostate cancer with Viadur (leuprolide acetate implant). · retained source version 1:2013-11-21:current:3adabdf22c4f0074878ebf878a390990d29a9ce5c084ca9b645f1c772165b15c ↗Source checked August 13, 2026
- Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi). · retained source version 1:2026-01-27:current:0e222d6c92cd228a89a1e8d098f48b6fda3ead24587cb3807fd950cf1f7afb6c ↗Source checked August 13, 2026
- Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72 to membrane. · retained source version 1:2025-06-05:current:2553f81ad2c494b3f3788088efbdd45a1051e96e75b866b4f9c39b6a82bfe393 ↗Source checked August 13, 2026
- Mitochondrial protein interaction landscape of SS-31. · retained source version 1:2024-03-30:current:b3ffbe4d2b68785b34396746632608b1d11128d5b301312fd7a79a15005eb7df ↗Source checked August 13, 2026
- Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases. · retained source version 1:2023-06-10:current:0bc72714a3df8dad13f4a074dbeb2ed4dc39e84cc3e7d874bcb71fc7e173df54 ↗Source checked August 13, 2026
- Molecule of the month. Exenatide. · retained source version 1:2018-11-30:current:0e77cf0c2496342a6c216f0af9ce59ef4aef0b8358bc0eb76fa5e0fcea3cfd3a ↗Source checked August 13, 2026
- MOTS-c as a predictor of coronary lesions and complexity in patients with stable coronary artery disease. · retained source version 1:2025-07-28:current:0c54b9030650f6655e85c03b05a08a59a6d324149945d774c5c59d6738cb86a7 ↗Source checked August 13, 2026
- MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. · retained source version 1:2022-10-19:current:f44551d20ee857a8a23667bd52fb4607d3512ae027055e1fdc04b1582fcbc5fa ↗Source checked August 13, 2026
- MOTS-c: an equal opportunity insulin sensitizer. · retained source version 1:2025-10-01:current:5f15a277b3f97428a1bb0a514f1d6001c62bfcbb4742e1e3e51935a0dae86d50 ↗Source checked August 13, 2026
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. · retained source version 1:2025-02-28:current:e07de435ff98d86c91ff4d25326c2ad13c22082310a85a36352e5b44ad05267b ↗Source checked August 13, 2026
- N-terminal degradation of ACTH(4-10) and its synthetic analog semax by the rat blood enzymes. · retained source version 1:2019-06-12:current:bcf51a4db7e85c094bd39c5e4d320925b1299982fe34778adfcef177a9ce9ddf ↗Source checked August 13, 2026
- New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA. · retained source version 1:2015-11-19:current:f4f416513809b8ff795e0180259b166a872da260c44318fe46bba825ad5eb5f3 ↗Source checked August 13, 2026
- Obesity affects circulating estradiol levels of premenopausal hirsute women receiving leuprolide acetate depot. · retained source version 1:2013-11-21:current:9fd559e7bf1eab2d16214d3c86f0fae69a53c7395ed9a4760e80c1e0228b7aae ↗Source checked August 13, 2026
- Octreotide in the Management of Chyle Leaks After Head and Neck Surgery: A Systematic Review of Cohort Studies. · retained source version 1:2026-07-21:current:1c4af7971ca871e2db6dbd7c52c76ef4827c4dd27f3de67197d22a1664a1c0fc ↗Source checked August 13, 2026
- Octreotide in the management of postoperative enterocutaneous fistulas and stress ulcer bleeding. · retained source version 1:2013-11-21:current:7884a3a635a8f6b15e581de2c3b146933b75e89218f32178aec2757304947dd8 ↗Source checked August 13, 2026
- Octreotide long-acting release in the treatment of autosomal dominant polycystic kidney disease: a meta-analysis. · retained source version 1:2026-07-13:current:bf553f1ffa0c8c84c4129b5d97ae42898b5397326628612409b90aa142616489 ↗Source checked August 13, 2026
- Octreotide therapy in patients with a left ventricular assist device and bleeding gastrointestinal angiodysplasias. · retained source version 1:2026-07-26:current:a81c06e69624f0499e8082fbfdee5af8c7f1da9ae0bf3534fca171d59d3fe24e ↗Source checked August 13, 2026
- On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT. · retained source version 1:2026-06-03:current:9f27e6800a3cff36bd0e6e2547002d20b2a5a3ffd2d59a42bab4aeb1b732099b ↗Source checked August 13, 2026
- Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. · retained source version 1:2016-11-24:current:635b9cdf9cc133e7bc7ea8702d983def1a91d3e44fcde7fdfc4ee6025676ba6f ↗Source checked August 13, 2026
- Optimization of automated radiosynthesis method for [18F]AlF-NOTA-Octreotide and PET/CT imaging in neuroendocrine neoplasms. · retained source version 1:2026-07-26:current:e43eb8f17c1859d0436c40570dd69daf25a449321adaf733fb9ec067d18ceebf ↗Source checked August 13, 2026
- Oral absorption of semaglutide: pharmacokinetic modeling and molecular dynamics simulations. · retained source version 1:2026-07-26:current:6a6c1eb0c3b8fc830a88387c71bd20250ed4e0fe35a894df6f10a0c44aacd161 ↗Source checked August 13, 2026
- Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption. · retained source version 1:2026-07-01:current:0269d960839cd7616fd270144fbde33cb4c37aeaccd65d50cff3af66fc847c1a ↗Source checked August 13, 2026
- Orthogonal HPLC methods for quantitating related substances and degradation products of pramlintide. · retained source version 1:2018-11-13:current:1c0111758a0b67dfe91a43f13502988b6cfd7dbaa2391ad4c9ba868f2154346f ↗Source checked August 13, 2026
- Ozempic and Wegovy Meet Congress: Political Economy Without Critique and Sociology Without Society. · retained source version 1:2026-07-26:current:2f7c53d73dc7a537fe865714b1de770ae3e3325d97fc0fcf93f9776ac9b49d23 ↗Source checked August 13, 2026
- Para-aortic lymphocele treated with an injection of somatostatine analog (lanreotide). · retained source version 1:2016-11-24:current:f00668d1cea11b16c76c7065f9b57f9e57a3ab91ba9651eda1d2ff6fa6219be6 ↗Source checked August 13, 2026
- Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report. · retained source version 1:2026-07-10:current:5adc8b896313640a52fb7fe92599f2cde17d398f9a9118b41f8407a5eef5af9b ↗Source checked August 13, 2026
- Patient and caregiver experiences with a patient-support program for setmelanotide treatment of patients with Bardet-Biedl syndrome. · retained source version 1:2025-06-11:current:ad972f169e992c541360bbf196f5a5a414536d4750243dfb1f1346e7d636f612 ↗Source checked August 13, 2026
- Pentadecapeptide BPC 157 and anaphylactoid reaction in rats and mice after intravenous dextran and white egg administration. · retained source version 1:2017-11-16:current:24a433f6539ce02eae7e09e35a0b5bf59f90517b9c0d8c20059d91eb629bb5d9 ↗Source checked August 13, 2026
- Perforating corneal injury in rat and pentadecapeptide BPC 157. · retained source version 1:2017-11-16:current:0965701b70f161f8a6d75b4226df6aedcbe1fabf131b71bb5debe56c70103960 ↗Source checked August 13, 2026
- Perioperative Management of a Patient With an Intrathecal Drug Delivery Device Infusing Ziconotide: A Case Report. · retained source version 1:2017-02-21:current:22b1d2807e79f8398c0854e46c9a1ad4e7368696847886674b7c5b558bf0eeea ↗Source checked August 13, 2026
- Permeability of blood-brain barrier to DSIP peptides. · retained source version 1:2019-07-12:current:2bd2ed0fc6508002a02dc67103349a50557f298f671c81a192c75ebe03442442 ↗Source checked August 13, 2026
- Persistence of romosozumab vs. teriparatide in Japanese older adults aged ≥ 75 years with osteoporosis: a population-based cohort study. · retained source version 1:2026-07-13:current:94464d7c3554ad2e6441b5e68666164e9ec330a5cb3f96f4b14d947ea54fa017 ↗Source checked August 13, 2026
- Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. · retained source version 1:2016-11-24:current:de734572405555069515bd20bf569a8f4ab82dab8cdfe697b81e65b01b8cdc07 ↗Source checked August 13, 2026
- Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. · retained source version 1:2026-01-28:current:56aee5479aad90be2c853daa9797be77c4e3025f182e9ebb69a30bb03dc8316e ↗Source checked August 13, 2026
- Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density. · retained source version 1:2024-03-31:current:7d0404213a0e8fa90c0adc92e9249edc2eae1da988a7357d53aeffa63c7c4166 ↗Source checked August 13, 2026
- Phenothiazine-Based Cu(II)-Selective Fluorescent Sensor: GHK-Cu Sensing Applications. · retained source version 1:2023-11-03:current:4d76ffc6ff31fd5522fd9ec704a33fa705e50cf1b34e666b4918ba99ad15d0c1 ↗Source checked August 13, 2026
- Physico-chemical properties of co-formulated fast-acting insulin with pramlintide. · retained source version 1:2019-12-10:current:f65dc847364b6c5b46300c0a5ec45dac8188f2502cd71822e77ab236712d0024 ↗Source checked August 13, 2026
- Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new? · retained source version 1:2013-11-21:current:b51eb4621813afe7992641f0c673678bed5182ff92e0ff74767c41f0abb1cec9 ↗Source checked August 13, 2026
- Plasma glucagon levels during spinal anesthesia and surgery in a glucagon-deficient patient. · retained source version 1:2004-11-17:current:031f093cdbf66a4da18602676953c123cdd3b8eea789cb39010f91e74653eb40 ↗Source checked August 13, 2026
- Poly(l-threonine-co-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide. · retained source version 1:2024-10-31:current:976b348c1d9174e60e56027e1e97f6b4f5a27999bb01a0f65a4bbd0b18a980d1 ↗Source checked August 13, 2026
- Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. · retained source version 1:2021-10-21:current:04a54e9cf404d6285e0ec8cffd340fa2780303f0bf8ba4a775cd16581b75403b ↗Source checked August 13, 2026
- Pramlintide as an adjunct to insulin therapy. · retained source version 1:2019-11-07:current:0ccb5ce04285642b3a517ba52c82c1d780d4029127a06cb7dc7e5f0e760806a6 ↗Source checked August 13, 2026
- Pramlintide injection drug product robustness studies. · retained source version 1:2018-11-13:current:ac0f19f7cf55af2454d24889217557d76a72e9d7eabdbfe5fef1777c304891b7 ↗Source checked August 13, 2026
- Pramlintide: (AC 137, AC 0137, Symlin, Tripro-Amylin). · retained source version 1:2018-10-25:current:3bbaf052810afe73b17d0c4d49e5da3f308319e834496da323416be38338a6d4 ↗Source checked August 13, 2026
- Pramlintide. AC 137, ACO 137, Normylin, Symlin, Tripro-amylin. · retained source version 1:2018-10-25:current:f5b06799125e81a9737603debfd9fceb63c724b6613e9c70f8d5bc8ab9e9911e ↗Source checked August 13, 2026
- Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. · retained source version 1:2016-11-25:current:d1ab9efa1869c48145852bbef1f2dde7fa559213e4a6dcbd278c26e3c2197c94 ↗Source checked August 13, 2026
- Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. · retained source version 1:2022-03-15:current:900a59f19c6ec3c2e62f436cec39fa89c6d909ecedce5887f501d4d6a698b301 ↗Source checked August 13, 2026
- Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process. · retained source version 1:2026-01-03:current:d175739d946bf90c08709844e4b3ab7f1a878cc7eaec47d229f6c041bc8af371 ↗Source checked August 13, 2026
- Properties of pramlintide and insulin upon mixing. · retained source version 1:2019-02-22:current:0795399ea0caba8b25e5b62e3abf166e5c678cd693f73bfbbddd0f082327780e ↗Source checked August 13, 2026
- Purification and characterization of DSIP-like material from ovine pineal glands: possible peptide-protein interaction. · retained source version 1:2019-09-19:current:c38fb68f0119385f2f9d66758fe740c4855d959ed76d6750f20f576f5cffa09d ↗Source checked August 13, 2026
- Radiation recall dermatitis in a patient affected with pheochromocytoma after treatment with lanreotide. · retained source version 1:2016-11-24:current:41f5c924b7a1f84c41e17edc6c5d700a24d57f42069129c82d2ae3ae65c7a91e ↗Source checked August 13, 2026
- Radioimmunoassay of DSIP-like material in human blood: possible protein binding. · retained source version 1:2019-07-12:current:8e4e577e0c098b5b546cdabacbc32e77c4b09cb2448dc3e03b49f733546e0d60 ↗Source checked August 13, 2026
- Radioimmunoassay of DSIP-like material in rat brain. · retained source version 1:2019-07-19:current:4aa369b11dd6b6dfaa4292d7420e48c4e7fd957bb980310c22a5b0389e8dd793 ↗Source checked August 13, 2026
- Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. · retained source version 1:2025-08-13:current:ec4057673cded7f347da2ac2d1e5cdf7f0cabec9e02eff227a89b03cae22538a ↗Source checked August 13, 2026
- Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157. · retained source version 1:2018-10-15:current:4edbe497a3cd68284402c57557108f4a5c927064357aa67783229fa63869d807 ↗Source checked August 13, 2026
- Readability and understandability of online patient education on semaglutide. · retained source version 1:2026-07-19:current:c63be2173d8713ff62ecb89ebb7d6e86270dd3767ef933715035ad6dfc1f6a35 ↗Source checked August 13, 2026
- Real-Life Data of Tirzepatide Use to Support Lifestyle Modification in Patients with Metabolic Syndrome. · retained source version 1:2026-07-16:current:b0a2ef558bea579f66d6855fb5f5ec4356393fc591f5218557d725856b6b5764 ↗Source checked August 13, 2026
- Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study. · retained source version 1:2026-07-14:current:9e8d0b6dc0ec5b29af04dce66a3650b6bec9431ade474120a354b9f8c093b70e ↗Source checked August 13, 2026
- Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China. · retained source version 1:2026-08-13:current:7e136182a1c9156a58d76ce0729d7a8c8312299eb1b72582609eea98f9738b39 ↗Source checked August 13, 2026
- Real-world use of oral semaglutide in adults with type 2 diabetes. · retained source version 1:2026-08-13:current:05635b809594af79f3aa90a345784c8a1a39f1dd87f9a2500d0629c15bff6c7f ↗Source checked August 13, 2026
- Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system. · retained source version 1:2026-07-17:current:2eacf6296f80723422e69ea69f8258fa20cfa7ccbe241af69354c66d9df6b4ca ↗Source checked August 13, 2026
- Recurrent ventricular asystole during octreotide infusion in a patient with pancreatic neuroendocrine tumor: a case report. · retained source version 1:2026-07-11:current:89d37d681eb0f90e7a6e9da78dc1c6b2a91172d75fd9888cb397a61a432cf632 ↗Source checked August 13, 2026
- Redefining peptide therapeutics with semaglutide. · retained source version 1:2026-07-16:current:d50762aa8e1dd707937323c10f300b350d7d8ce3358d3b43571ebdf1bfa50120 ↗Source checked August 13, 2026
- Regional distribution of glucagon-like immunoreactive material in the brain of rats and sand rats. An immunohistochemical investigation. · retained source version 1:2005-11-17:current:9abb0797668cf285a7900e0042af2f2eb0dc508d1413812e6d52e8b2969772e6 ↗Source checked August 13, 2026
- Residual gastric content after tirzepatide discontinuation: is one week enough? · retained source version 1:2026-06-22:current:992ec890b43eefa524f446c306c946ef7019d370c251e7903d960fd4e60e04f0 ↗Source checked August 13, 2026
- Resolving bile reflux by lanreotide in patients with Roux-en-Y gastrojejunostomy. · retained source version 1:2016-11-25:current:3b8876273c12a6d08cc0986b7b690557871d063c3aef043e774b3fd53362c4d3 ↗Source checked August 13, 2026
- Retatrutide. · retained source version 1:2025-09-02:current:c4c56d13eeff24f50c6711af686c5400a993521d67b44b6b64e77b4c5e96506d ↗Source checked August 13, 2026
- Role of glucagon in metabolic diseases. · retained source version 1:2026-08-13:current:8ce05f3c7a5b825fa1a8c09909cf8056d97b83e7dadb3496653e3481b77d1e9a ↗Source checked August 13, 2026
- Self-assembly of the octapeptide lanreotide and lanreotide-based derivatives: the role of the aromatic residues. · retained source version 1:2016-11-24:current:5a8e6635b4fc6de6d93dfa013308136a7a3ec12c729fe7071c4666d40bbc6d72 ↗Source checked August 13, 2026
- Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice. · retained source version 1:2026-07-11:current:03a19401f44cfd6338ba59075c0ac32635ab5e2c848d0f4a277dffd88998117e ↗Source checked August 13, 2026
- Semaglutide in patients with hidradenitis suppurativa and obesity. · retained source version 1:2026-07-11:current:9d1a9810bc26f3fdbf706a17c999acd212b6ee3e63cbbaec0c9230c1a208c9fb ↗Source checked August 13, 2026
- Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial. · retained source version 1:2026-07-26:current:3133e70acd79edb4b7f07f32ba5182143ff7ffe3cf69f13ad7a4ad7ff788b5a9 ↗Source checked August 13, 2026
- Semaglutide treatment for children with obesity: an observational study. · retained source version 1:2026-07-14:current:925c3b5c4f3b0aa3e170402d93fbf080644f573deaf649f2621e5090bb87a99f ↗Source checked August 13, 2026
- Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials. · retained source version 1:2026-07-26:current:e594bc76839100b1f0657dc359621e707f00b1ed715392107f51cc07f26ba667 ↗Source checked August 13, 2026
- Separation of tryptophan from DSIP, a Trp-nonapeptide, by adsorption to aluminum oxide. · retained source version 1:2019-06-28:current:77db209931eda5cbb7d5186063db099cb161acbb1cef2b8f1517e71a277b85c6 ↗Source checked August 13, 2026
- Serum MOTS-c levels remain unchanged in patients with preeclampsia. · retained source version 1:2024-10-29:current:c6650fed2f452d9e869dea3d74e831e95eaf889d97c3594169be7b428d1f8699 ↗Source checked August 13, 2026
- Setmelanotide (Imcivree) for rare genetic forms of obesity. · retained source version 1:2021-09-28:current:916f0e404042939b035f3cabb3bb7fc592001cc3ea454a2362c6be24e22babea ↗Source checked August 13, 2026
- Setmelanotide Acetate. · retained source version 1:2021-09-29:current:370a1d7711c193d63447357a8c06f5891673c8b04936838027131b8f9fa6c8ad ↗Source checked August 13, 2026
- Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. · retained source version 1:2025-05-21:current:486d47792a4b58d582a695ac80e7fda867c70c8c71e0782d257403cda7cc77fc ↗Source checked August 13, 2026
- Setmelanotide for the treatment of severe early-childhood genetic obesity. · retained source version 1:2024-12-27:current:400f196b9bc1aaa495f22ac5999c4530ddd82645cd57b1e3f6239bd8c153742c ↗Source checked August 13, 2026
- Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction. · retained source version 1:2024-11-21:current:a62ab4e03e3df4800537cd2efd1f5f2fde4fe82119d9454f331541a32db0c2de ↗Source checked August 13, 2026
- Setmelanotide: First Approval. · retained source version 1:2021-10-11:current:afa3d97ef8b8c9f411fecf06faee8e28eec64902803b9da85eb39f413fe7b596 ↗Source checked August 13, 2026
- Setmelanotide: new promise for the treatment of hypothalamic obesity? · retained source version 1:2025-05-21:current:6efa835d669fa42cb097c158573de2ee5fdf145a928c986a5edc7f8e1d36510c ↗Source checked August 13, 2026
- Setmelanotide: what does it mean for clinical care of patients with obesity? · retained source version 1:2021-07-21:current:787ee1ec4390f50b27dc66b9d0a2de6ee71aeb6d9dc5188e77ef1abd17469d79 ↗Source checked August 13, 2026
- Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1. · retained source version 1:2026-07-16:current:62931f6734d20b2a14d7915bc2c92be693efcfa2c72a1a981b7358830d345b81 ↗Source checked August 13, 2026
- Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada. · retained source version 1:2025-05-28:current:a8c145865e45418886dc1496431487575f6060e42a7c9b6422afec70f839e879 ↗Source checked August 13, 2026
- Site of glucagon in the islets of Langerhans of man as studied by the immunofluorescent technic. · retained source version 1:2004-11-17:current:c2c6a7207bfa677cd6e25c4955d4fe7233af72a8487204757b99778da78d5456 ↗Source checked August 13, 2026
- Specific binding of semax in different regions of the rat brain. · retained source version 1:2019-09-22:current:0198d9557449aad16fe290e33b4c78842d9abc240fb1f92fc7f1d50cb660f607 ↗Source checked August 13, 2026
- SSTR-Mediated Precision Delivery: Overcoming Triptolide's Limitations through Octreotide Conjugation in Pancreatic Cancer Treatment. · retained source version 1:2026-07-26:current:0740748f7a717201eedfa109dd44c79da1b133801e2a478853090f5b4dfc5087 ↗Source checked August 13, 2026
- Stability of Semax acetyl to proteolysis in various biological media. · retained source version 1:2021-10-21:current:54c165359f918cc37ab57059ea7e83e313c8c8bbcea412dff0c152fcc763f949 ↗Source checked August 13, 2026
- Stable gastric pentadecapeptide BPC 157 and bupivacaine. · retained source version 1:2017-11-16:current:ee0f5020ea9ef9530f6716e5249216d5579d60b7997f6c558d4f7965022970ac ↗Source checked August 13, 2026
- Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation. · retained source version 1:2019-06-04:current:eba94700db3c8b27965e65add849e566ff8bd3669f6c445fac24ff7178a356ca ↗Source checked August 13, 2026
- Stable gastric pentadecapeptide BPC 157-NO-system relation. · retained source version 1:2019-07-28:current:64b14098b8a9bcbaba42da36200390642ba99bd1e5fa3c5e9b0c8472eb19aa82 ↗Source checked August 13, 2026
- Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution? · retained source version 1:2018-10-04:current:5724dd5683c210f15baaa24244331fa8cc65454da0594620c3087a4924b428c8 ↗Source checked August 13, 2026
- Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor. · retained source version 1:2022-10-14:current:6fd161d3c3895b07649d0e651156a67a67a8653466609e25db6a65bc9deeb9a7 ↗Source checked August 13, 2026
- Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. · retained source version 1:2024-07-20:current:497b93ace79d837dda2b256a32f24f2a382bd85111476943a7b6d1a57b056d33 ↗Source checked August 13, 2026
- Study of proteolysis of Semax analogues with different N-terminal amino acids by carboxypeptidases. · retained source version 1:2021-10-21:current:c39a899a89a348dd8fe54c4470202ccbcfbd352fd55dadfe0e7672b802485b83 ↗Source checked August 13, 2026
- Study on the neurotropic activity of the products of Semax enzymatic degradation. · retained source version 1:2016-11-24:current:f30cf5aa234ab2f1bd044b97e0e5bbbdc70df718bd4b06e7693a3ff6ee02c279 ↗Source checked August 13, 2026
- Summaries for patients. Exenatide therapy for type 2 diabetes. · retained source version 1:2026-01-28:current:cafd6188ea6e31e5e24be5083ddd428cbf8512bb747aad863da81df1d22ae551 ↗Source checked August 13, 2026
- Supramolecular Peptide Depots for Glucose-Responsive Glucagon Delivery. · retained source version 1:2026-07-13:current:e2b1fe5af40c0e1f711ca5a85bb3f735aeca0fec407a198498b0f04b55f0eb9e ↗Source checked August 13, 2026
- Target-mediated drug disposition modeling of liraglutide in rats: Implications of target engagement for pharmacodynamic predictions. · retained source version 1:2026-07-15:current:05276097d6c1a00a2d540b0a434104a9edea158261ba2ba03cb2e439cc9ec1c5 ↗Source checked August 13, 2026
- Targeting mitochondrial dysfunction with elamipretide. · retained source version 1:2025-07-28:current:d0cd8ca6d86eb3d7a9c74d20b8872ca6cc919ff747b82d0e549548f5293b20aa ↗Source checked August 13, 2026
- Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide. · retained source version 1:2026-01-27:current:ef04fef6bbce780c54d2423f0287143002ff5923f9b441943d7d0b72788af6cf ↗Source checked August 13, 2026
- Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. · retained source version 1:2013-11-21:current:b275f25320218cc5a24086db6b1a89e3a2a90793f8acea334fd2d8828f69a99a ↗Source checked August 13, 2026
- Teriparatide (Forteo) for osteoporosis. · retained source version 1:2013-11-21:current:3c10d9a635b93b7825eb6c5fe75d6e62f8ba99a9822457cc6e607414777750c5 ↗Source checked August 13, 2026
- Teriparatide (forteo) for osteoporsis. · retained source version 1:2013-11-21:current:dddce1ceb37366550dd5994cf5fdf17694c4efe10a1757d3437b12075e4497f7 ↗Source checked August 13, 2026
- Teriparatide (rhPTH 1-34) for the treatment of osteoporosis. · retained source version 1:2013-11-21:current:159383b72e577850a74233f628fbed57e0ff0a5df42fb3325ec5003098d90fc2 ↗Source checked August 13, 2026
- Teriparatide for postmenopausal osteoporosis. · retained source version 1:2013-11-21:current:1a9eea2a3956c3f4159f4466e89b99a923eafe806e5cb9e81cf3a771768da3ca ↗Source checked August 13, 2026
- Teriparatide for severe osteoporosis. · retained source version 1:2013-11-21:current:5d080718744b8cd30dc5f6f18f0e1adc732449dd2e212c9737105764ae577a26 ↗Source checked August 13, 2026
- Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial. · retained source version 1:2026-07-15:current:b413e30416a35b6b7cbd6cd1f0e8f020dd1cb507da91e5910b8c165b3df61cc9 ↗Source checked August 13, 2026
- Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: Research Summary. · retained source version 1:2026-07-14:current:381aa989bff10cc48bf0b5541140d580d790babd29f47878456612c2b50185e0 ↗Source checked August 13, 2026
- Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid. · retained source version 1:2013-11-21:current:932218b3a6d3317d8cde8349f2abe234898b80e2beb616230a1b4c70c879c8ad ↗Source checked August 13, 2026
- Thanatophoric Dysplasia Type 1 Treated with Vosoritide: A Case Report. · retained source version 1:2025-11-21:current:bdd8317a058752ace60dd5def00e9684f8974b5db82671dcc639eec3b6437a78 ↗Source checked August 13, 2026
- The early rise of plasma growth hormone (HGH) and immunoreactive insulin (IRI) in children following intravenous glucagon. · retained source version 1:2004-11-17:current:9c91918302f2e68a796586c89c70d873de281423dc562f2bf022763b406a78d7 ↗Source checked August 13, 2026
- The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics. · retained source version 1:2026-01-28:current:7c349d2f6922dcea2ae458915b5105a1f34566a9abc6397bad41a1e51f3f9085 ↗Source checked August 13, 2026
- The glucagon content in tissues of the human intestinal tract. · retained source version 1:2004-11-17:current:379dbf2a7753b898b85dbdac93633987199a974a1a6406dd5d3563972b7a99ec ↗Source checked August 13, 2026
- The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. · retained source version 1:2026-01-28:current:3e72b3fa3f9c4ebeaaeb4044c4fb990150d3ebd374a1924a88a38d065e11ef49 ↗Source checked August 13, 2026
- The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. · retained source version 1:2024-08-27:current:0dfdd718791c353393bff8e2f5927162ff9285d69b931d00fe15c37189919c0d ↗Source checked August 13, 2026
- The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? · retained source version 1:2022-12-07:current:a34dc3f9abc370a2942e83e8fd5efa7627f5430d30d0947006ed9fa2099aadc6 ↗Source checked August 13, 2026
- The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. · retained source version 1:2021-10-21:current:7ccc75669b0b8a5c80bbb2e86accc6419d6a48c6d87b1cc40397c80a9bfca71b ↗Source checked August 13, 2026
- The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. · retained source version 1:2022-06-27:current:9892b6829fd8d121aa34f553e22fa491b627703b3fd97ce19276e0a78b01937b ↗Source checked August 13, 2026
- The silent rise of self-prescribed semaglutide use among non-obese young adults in the Middle East. · retained source version 1:2026-07-23:current:23f4664a58be15d09ef51e43564a4d2a4ae11e80dfc469ccdb96966ddd06d5a6 ↗Source checked August 13, 2026
- The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice. · retained source version 1:2026-07-16:current:aa13c6d0601990fe27908ec2190cc891d6785255d9ce72d2a1d602450ec63dc1 ↗Source checked August 13, 2026
- The use of abaloparatide to treat nonunion following dorsal closing wedge osteotomy for Freiberg's disease: A case report. · retained source version 1:2021-11-18:current:8cb15da888f6aa7693e4b4d7b4ce171812f325e0cde82bea8d9d71ec1c87cce9 ↗Source checked August 13, 2026
- The use of exenatide in severely burned pediatric patients. · retained source version 1:2026-01-30:current:7b0beb1fbf52b273a754c768e57936816d8a606457c5a5b5cf242be087ddd64f ↗Source checked August 13, 2026
- The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults. · retained source version 1:2026-07-26:current:901b44be3e2553d33938699b02bb6c52359918d847ca9fad5a4d18b6422d532e ↗Source checked August 13, 2026
- Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats. · retained source version 1:2016-11-25:current:695da151220066cdbfe3d0b90f22a4c1ea7783871cba56aad6e8c6dcb80f95b1 ↗Source checked August 13, 2026
- Therapeutic possibility of "Semax" for depression. · retained source version 1:2026-01-28:current:bf119eab6489c747b99de8df515ca73a0e778454eff4144564731b2ebbc2fa67 ↗Source checked August 13, 2026
- Three-dimensional craniofacial imaging in children with achondroplasia treated with vosoritide. · retained source version 1:2025-12-06:current:41eb6dc0e2d47be6ed2a7b30cfaf650280ec382b5a9c4fa147effdbf8cd0a30c ↗Source checked August 13, 2026
- Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis. · retained source version 1:2026-07-21:current:0c36391443de329ea9a7675bab87c829513f88ce96911e839bd78d6c6f73931a ↗Source checked August 13, 2026
- Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. · retained source version 1:2026-07-06:current:0be4c46fb1db5dd7a823239f52996064b0f0e5eb4c465d7a56b8e7eacf80a4db ↗Source checked August 13, 2026
- Titration and discontinuation of semaglutide for weight management in commercially insured US adults. · retained source version 1:2026-07-26:current:fe094647205bf41c28e96b4efc5c33bf0f00151b9d85f0e799aeff274688afd5 ↗Source checked August 13, 2026
- Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis. · retained source version 1:2026-08-13:current:9b700312a14f671a8c03ede42aabc4766ec4c0dbf1b1d65e07dc16ecbc35f50a ↗Source checked August 13, 2026
- Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration. · retained source version 1:2026-06-17:current:0af0096608e26ee1c91dc42ccbddb478e5b130c0bbcf3b7f2b649bc406458578 ↗Source checked August 13, 2026
- Total Chemical Synthesis of Glucagon Glycoforms Reveals the Remarkable Influence of Natural Glycosylation. · retained source version 1:2026-07-21:current:9f2fdf035bae7dff732b783205449cc95a6b0b003fc45b5ae5db41e969395f61 ↗Source checked August 13, 2026
- Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System-Triple NO-Agent Approach in Rats. · retained source version 1:2026-01-31:current:5a8eb6d69a7d7a5fe0ed2260198d197a3df44ead9f9155d09555b7479d294870 ↗Source checked August 13, 2026
- Tracking Insulin- and Glucagon-Expressing Cells In Vitro and In Vivo Using a Double-Reporter Human Embryonic Stem Cell Line. · retained source version 1:2026-07-21:current:66ee4756e64197c37a394d38dd296f995b401df90686fbe738c0fb2d4acd8c5d ↗Source checked August 13, 2026
- Transient teriparatide for postoperative hypocalcaemia with hungry bone features. · retained source version 1:2026-08-13:current:0f6ffb1496a74165eb5c939d991b5700d438f11e534205cbca1b357615213068 ↗Source checked August 13, 2026
- Transport of the synthetic peptide DSIP through the blood-brain barrier in rabbit. · retained source version 1:2019-06-29:current:2b7b4bc967fa868b381ad202aeca0b9a6d4b8cb288f90ebd42623869b2ee8133 ↗Source checked August 13, 2026
- Treating osteoporosis with teriparatide: many unknowns? · retained source version 1:2013-11-21:current:7cc6c1e3eefbf7aa612637536bf387f720983446fb6be27606cd935fff57347f ↗Source checked August 13, 2026
- Treatment challenges and complications with ziconotide monotherapy in established pump patients. · retained source version 1:2026-01-28:current:c4a20b271d4b4ce4b824a84c57d41f18faad63d4fd61f59f9658ffafd71d81f9 ↗Source checked August 13, 2026
- Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide. · retained source version 1:2013-11-21:current:6dc35141afcdc0b22a07f8e845f2512f6d8bc24fe2246b7dcaddad601b6aa56a ↗Source checked August 13, 2026
- Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey: Patient and Provider Preferences for CPAP and/or Tirzepatide. · retained source version 1:2026-06-26:current:972a07d8c39aec262c1fb4710b5a3bc67b9442d90a78531f2203140e2d7f672c ↗Source checked August 13, 2026
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity. · retained source version 1:2025-07-03:current:b72d53d465bdbd32536001339546ddb5df25fdfa26c478f1010e16cab430a9d8 ↗Source checked August 13, 2026
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity. · retained source version 1:2025-07-03:current:b87e839b7f0d2919fa663ded33830ecd0aa7bac20cbae379414a73c43c6bf563 ↗Source checked August 13, 2026
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply. · retained source version 1:2025-07-03:current:99a9ba7853606c489dc7e3178591fcfcd9c0129419b674f26c070b90c7a3f411 ↗Source checked August 13, 2026
- Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. · retained source version 1:2024-08-01:current:64bb23e1c9c8f11b6337187f517b58fd2462927360cf6103bafd4b901fd57a34 ↗Source checked August 13, 2026
- Understanding Weight Regain After Tirzepatide Withdrawal. · retained source version 1:2026-06-01:current:9d04721a216ff4e95bbf2d266c3aed0b94d6e5aee47f97e709364f28a631eaf0 ↗Source checked August 13, 2026
- Upper endoscopy and glucagon: a new technique in the management of acute esophageal food impaction. · retained source version 1:2004-11-17:current:ce131d6c26a2ac3d88e389e9e2c190091cf058fd511d5fee533e933445599c79 ↗Source checked August 13, 2026
- Use of dulaglutide in a pregnant woman with type 2 diabetes until third trimester of pregnancy. · retained source version 1:2024-11-05:current:ac3e203c860189e07048cca6ff4027b5b2ccc8713e68d945bd17c01c8584ba4b ↗Source checked August 13, 2026
- Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases. · retained source version 1:2023-08-15:current:e16bd31c7efe85af39f6925d450be2c40995adc030ee26b5f59976caa2b3241f ↗Source checked August 13, 2026
- Use of lanreotide for the treatment of gastrointestinal fistulae. · retained source version 1:2016-11-25:current:1cfb22a9d3870b7e907b6c3480a09dd7e6742cf8575e41228be2f61f4790dd9c ↗Source checked August 13, 2026
- Validated chromatographic method for the simultaneous determination of eight drugs (morphine, ropivacaine, bupivacaine, baclofen, clonidine, sufentanil, fentanyl and ziconotide) for intrathecal analgesia. · retained source version 1:2026-01-27:current:26aeb50d9f2e3ad8e10ae4475c2f82df2a93e3f6533392b679b5b524fcd8e1ed ↗Source checked August 13, 2026
- Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence. · retained source version 1:2025-09-14:current:4938cf1e9128c471ca8d22eb6eaa0171dcec187c891f924c24a2e7274a85a8b9 ↗Source checked August 13, 2026
- Vosoritide therapy in children with achondroplasia under 5 years of age. · retained source version 1:2024-10-15:current:9a2858135bc6c8ba0438e22075b540880f790ca352714f88aa9ef9a5f9ad9d08 ↗Source checked August 13, 2026
- Vosoritide treatment for children with hypochondroplasia: a phase 2 trial. · retained source version 1:2024-05-31:current:6d8eb21733536154b2fbd0b03f996b9f94417823e884956e818fd1610cc6f852 ↗Source checked August 13, 2026
- Vosoritide: First Approval. · retained source version 1:2022-02-14:current:9c85d601ee773d20870cbc92fb473185a4051d91a658c2d407a1fb87604a349d ↗Source checked August 13, 2026
- Vosoritide. · retained source version 1:2022-03-16:current:f1d4c7428c10cd2a686971423f41d8f0d756f3ea86e8a0cf68f0b0e2f381212f ↗Source checked August 13, 2026
- What the Scale Does Not Show: A Patient's Reflection on Semaglutide, Strength, and the SMART Trial. · retained source version 1:2026-07-26:current:cc893d47a8ba0020a019a1c6566d448ab12e7ff7b028d907c439d3b5f3fa735a ↗Source checked August 13, 2026
- Ziconotide for treatment of severe chronic pain. · retained source version 1:2026-01-28:current:804e779e8bf28030b6decb10e048c10405d03701c6f818c8b31a914cb5636716 ↗Source checked August 13, 2026
- Ziconotide: a new option for refractory pain. · retained source version 1:2017-04-27:current:77de67ac0c433595c9ffcb4d43d15e50bf2b946aa038705e5d7ee57af18b8639 ↗Source checked August 13, 2026
- Ziconotide: can we use it in palliative care? · retained source version 1:2026-01-28:current:d8665a67d2240a68f2b8141af9e9bf7a2c9cc3ecfe2778970d37801511bd6264 ↗Source checked August 13, 2026
- Ziconotide. · retained source version 1:2026-01-28:current:0543acb589bd2af5f50242ac42f7f76e97c84cb3b4a1896338422032a3e6f685 ↗Source checked August 13, 2026
- Ziconotide. CI 1009, SNX 111. · retained source version 1:2018-10-25:current:f36b376fb3acef3baa81b16a002fdfec4f0038077e02064e490148ba5ab22100 ↗Source checked August 13, 2026
- Zn(II) - pramlintide: Stability, binding sites and unexpected aggregation. · retained source version 1:2018-03-13:current:27ff847eb948d5f6cc9cf5503a0fe911f4be5a1b866dcf7dd2e59f364a6fd8b6 ↗Source checked August 13, 2026
- β-Cyclodextrin derivatives bind aromatic side chains of the cyclic peptide lanreotide. · retained source version 1:2026-05-17:current:2f1f823680fcb8de0f2d773287c3601a31267253146e281c68f7ccfde6c15a00 ↗Source checked August 13, 2026
- PubMed record PMID 10199803 · retained source version 1:2016-11-24:current:76dea1f9256112b5eda8a255d04c9423185ffaed69ddb48a1990c5e8257af88b ↗Source checked August 12, 2026
- PubMed record PMID 10231313 · retained source version 1:2016-11-24:current:178cd55ce816401ca205e1489151ed72fd7a9b5989ba13d4869fc9a3e3a18639 ↗Source checked August 12, 2026
- PubMed record PMID 1027323 · retained source version 1:2004-11-17:current:816aca0a1723d85c2906962b7c4a983daeaf9f06d1e41711ae644acda923d3bf ↗Source checked August 12, 2026
- PubMed record PMID 10416065 · retained source version 1:2003-11-14:current:a0b01b26468876923fe76c0c7c2351778537bb8be9bb00a4a05f9abeda7bc374 ↗Source checked August 12, 2026
- PubMed record PMID 10480146 · retained source version 1:2016-11-24:current:a6992ef38b334ea48031c7529594c6f1460d44f376a78659b8b6ce56f4089d3f ↗Source checked August 12, 2026
- PubMed record PMID 10496658 · retained source version 1:2019-08-18:current:2e852a5a44c2cf078ee98f8fbf94ee090aa5c4d986b0b233e475478bb658555f ↗Source checked August 12, 2026
- PubMed record PMID 10576958 · retained source version 1:2013-11-25:current:1452aed5ee4ef16c3eb6908c8a0c6c525fe654bb54a8e374bb714f5eb05a92a2 ↗Source checked August 12, 2026
- PubMed record PMID 10579475 · retained source version 1:2016-11-24:current:df147568030cab6debe59bddb1c407a0237df703ef60b49b71908ad6f9eddb5e ↗Source checked August 12, 2026
- PubMed record PMID 10667403 · retained source version 1:2003-11-14:current:77796393df92c78adc992aed56d3affb61cd6187c18f7619b4727323562c2cb0 ↗Source checked August 12, 2026
- PubMed record PMID 10748802 · retained source version 1:2016-11-24:current:b9eb4c4764bf8767e9032aebf1a3a2d299f9ce1c52145f2108953a1b27b5c549 ↗Source checked August 12, 2026
- PubMed record PMID 11059665 · retained source version 1:2016-11-24:current:0eb4664ff6a397af79b0530240786246d5547044586a870e3a4ca750e4559079 ↗Source checked August 12, 2026
- PubMed record PMID 11087911 · retained source version 1:2019-08-31:current:064e69818fb65978b25faa9d1b1cdf871973c86518047a741439b6cd2dad5f15 ↗Source checked August 12, 2026
- PubMed record PMID 11095353 · retained source version 1:2016-11-24:current:335788b8d858df99a7bbfcfcd803f0ab5c9f267069b529f99cca7ac417d81819 ↗Source checked August 12, 2026
- PubMed record PMID 11128563 · retained source version 1:2016-11-24:current:fd723ce8d43acff90a3d9d66dda6f4b6eba7e0a56024515e5b4a750cf3fccfaf ↗Source checked August 12, 2026
- PubMed record PMID 11188738 · retained source version 1:2008-10-08:current:c3228a953edeaae00000fa430d8889c70e984b1d1c94fc381c747c761557cf8c ↗Source checked August 12, 2026
- PubMed record PMID 1122835 · retained source version 1:2004-11-17:current:f8f2e5f4d592b6e053ecc49d3f8daf4aa8aa44813f1fc0b5fc05b68969fe2f92 ↗Source checked August 12, 2026
- PubMed record PMID 11459660 · retained source version 1:2019-08-19:current:ed4aadeae3a232d10f7351ca120efb595b5cdaf187da0e448b183dd59faf18a3 ↗Source checked August 12, 2026
- PubMed record PMID 11525128 · retained source version 1:2016-10-20:current:a9643d652195c81e72ce97327227acd989351e15bb8a62b4d84f7f9811040907 ↗Source checked August 12, 2026
- PubMed record PMID 11548444 · retained source version 1:2013-11-21:current:0d1da2794f148b62b8baafd79d85fa5f041658db431ffefea237aeeaafe50389 ↗Source checked August 12, 2026
- PubMed record PMID 11569188 · retained source version 1:2010-11-18:current:6790e3d4f716baf1324b3ffd5275de24ebf415e9efd8aa4caefcae12dc02c9c2 ↗Source checked August 12, 2026
- PubMed record PMID 11710342 · retained source version 1:2013-11-25:current:0bc149053645b30ed8badf50c6b245397e484fcd8f8ada88851da02227027116 ↗Source checked August 12, 2026
- PubMed record PMID 11763160 · retained source version 1:2013-11-25:current:0239b942b1ea06e11b8a9577519c7576aa7c2611361e74d0afd63c51f85b8d48 ↗Source checked August 12, 2026
- PubMed record PMID 11927761 · retained source version 1:2016-11-24:current:618dcf9dbacae047701e78b0409e82d3eb431087dd5dccad09c1f309ef2a6b3e ↗Source checked August 12, 2026
- PubMed record PMID 12017422 · retained source version 1:2013-11-25:current:034d693383f43e30e3b354d4a16133468806a569b6b6dcd5965e260c0af0bc82 ↗Source checked August 12, 2026
- PubMed record PMID 12049808 · retained source version 1:2019-07-20:current:4d521f3dddca481906dd89b64af2dde84ae0d1b19054f6e2fc072ce5a276ec13 ↗Source checked August 12, 2026
- PubMed record PMID 12079622 · retained source version 1:2013-11-25:current:92e79dc62b04f762da797bd33ddc61eb67f050d6140123444d467fef87904267 ↗Source checked August 12, 2026
- PubMed record PMID 12101568 · retained source version 1:2017-11-16:current:0318a04ccd3814fe770c621f39c98c598ae762325e97facde607c8e474491fd6 ↗Source checked August 12, 2026
- PubMed record PMID 12209581 · retained source version 1:2026-01-28:current:fcd60a58c522cda298f3e40ba58b4c44b0da68c2c7189683d2c0f547c2d3f3c4 ↗Source checked August 12, 2026
- PubMed record PMID 12817525 · retained source version 1:2016-11-24:current:407df54229e0e8a5753233472b7cfd24a29c961bdb0781297a441ff718367c73 ↗Source checked August 12, 2026
- PubMed record PMID 12851303 · retained source version 1:2019-06-16:current:dadc1780d730ddf4c85c5a6e341d7a0a9ce3fd9b65d4d79c85f27d3b2586a7d3 ↗Source checked August 12, 2026
- PubMed record PMID 12942748 · retained source version 1:2016-10-20:current:f4939470d8a7449b1e3ce81cbccf53a291b1b6853230b166957ed54595946c64 ↗Source checked August 12, 2026
- PubMed record PMID 1407643 · retained source version 1:2013-11-21:current:dc682fb60f40b68609ee1b37f201bb36b5acf77d5e8d223dfe7e1cf5bb88e7e0 ↗Source checked August 12, 2026
- PubMed record PMID 14501183 · retained source version 1:2019-11-08:current:202bb7327a3960569c770815b74159d82bbaf0cb48cded1fb73a760bbf4f0d43 ↗Source checked August 12, 2026
- PubMed record PMID 14653248 · retained source version 1:2013-11-21:current:a4deb1c0ebafaf8a16066773d0ea2355a00c308f7d785010fa63f4fb2596ff9f ↗Source checked August 12, 2026
- PubMed record PMID 14737746 · retained source version 1:2013-11-25:current:f0cc63f78a2ca40abd325a89cedf8a2e9a6c51d69f3f4f4de97d64098f274c7d ↗Source checked August 12, 2026
- PubMed record PMID 15016242 · retained source version 1:2004-03-12:current:89958d58004e5b411ff62a6e9623d9541db0afb4e09fa9a178285fe95cb1c6f9 ↗Source checked August 12, 2026
- PubMed record PMID 15080976 · retained source version 1:2004-04-14:current:9e6411831fadedf377e6c86508bbf89887503d9d30bb1356c29a4f1b0700fcd4 ↗Source checked August 12, 2026
- PubMed record PMID 15188751 · retained source version 1:2013-11-21:current:ae42055faa12561d382496c929fec58db3a60164fd3837432159cd42f3759290 ↗Source checked August 12, 2026
- PubMed record PMID 15299336 · retained source version 1:2007-07-24:current:fc8edabdf66eb86cb5ba9468aabaded05251011c0e0bc0b3b97bb8058a874dd4 ↗Source checked August 12, 2026
- PubMed record PMID 1533022 · retained source version 1:2013-11-21:current:7d3e15e575d19c85346afdb391a9cf6956726651aa51e77346cf8024a17695bf ↗Source checked August 12, 2026
- PubMed record PMID 15381050 · retained source version 1:2017-11-16:current:24dfaf1db9e4ff7a77f1e5b14dca56f6a026e172a40e6b0bf462a86f813b0e6d ↗Source checked August 12, 2026
- PubMed record PMID 15490730 · retained source version 1:2016-10-21:current:bd5f34c7610600ebeb4041010d6981d6ff757ae8544ca917ebdbff97ca4f84f0 ↗Source checked August 12, 2026
- PubMed record PMID 15774286 · retained source version 1:2017-11-16:current:ce9452e18592f30e13879c6df17836bae5e5e9557343690d382e208515931dd3 ↗Source checked August 12, 2026
- PubMed record PMID 15840402 · retained source version 1:2017-11-16:current:8363d0cb78919474ae1fd5d356684136d74e06bd1c8e4c15824c4e931d8f11fa ↗Source checked August 12, 2026
- PubMed record PMID 15912124 · retained source version 1:2013-11-25:current:f59dc7dc49d9d4149c70d4e5b708d74d6c9cc97b611717b6980218889f1f4801 ↗Source checked August 12, 2026
- PubMed record PMID 16050943 · retained source version 1:2013-11-25:current:5a680c36b8ca4202809cb7b737f595255d9aa25498c4565521a25a7b40f06c4f ↗Source checked August 12, 2026
- PubMed record PMID 16117343 · retained source version 1:2017-11-16:current:ed333093e89c4839cb0fd6b4085910d22fe3d18fc8e5af3c83e4b6c371db1512 ↗Source checked August 12, 2026
- PubMed record PMID 16207099 · retained source version 1:2016-11-24:current:f9cf13f2140763b1cd455da78b664687b2adf45f181e356114822dbc42969b8a ↗Source checked August 12, 2026
- PubMed record PMID 1621201 · retained source version 1:2013-11-21:current:2af2f52a8b363beb2f0aee9c16db7cb714a8b49b937b557e8d28ed12f39a2863 ↗Source checked August 12, 2026
- PubMed record PMID 16331245 · retained source version 1:2016-11-24:current:6b5b0c184ef3f1925ea4466c8c723dc1b20d109dff05a2d7e08b907805504316 ↗Source checked August 12, 2026
- PubMed record PMID 16369461 · retained source version 1:2017-11-16:current:54b12fac6ada69d38b3b8be29e12e6423195b0d60f905b7a1bbcaf4a1f9f803a ↗Source checked August 12, 2026
- PubMed record PMID 16503720 · retained source version 1:2016-11-24:current:7e1deef883722bb6c94cbdad027d9496f9e747a6f238758275f967fc51c75a6e ↗Source checked August 12, 2026
- PubMed record PMID 16539679 · retained source version 1:2006-11-15:current:55279a7d08e84c8bf8745b88a4193fd8a467eb9b0ca972fc365ae3af7b325c60 ↗Source checked August 12, 2026
- PubMed record PMID 16583442 · retained source version 1:2017-11-16:current:549174e1aa21a4a274f00c885ee5187bc5214522ea0d6b4b1e93933caa954202 ↗Source checked August 12, 2026
- PubMed record PMID 16609979 · retained source version 1:2017-11-16:current:d143c2440ac6614efd7e82b93f4d4d8dfec26f74ec8ea086d9a72647a3e1ce7d ↗Source checked August 12, 2026
- PubMed record PMID 16635254 · retained source version 1:2013-11-21:current:97bab8027cc3eb7058193f3c3b72ba172e29af045f2fbfe60265ae7c194bc493 ↗Source checked August 12, 2026
- PubMed record PMID 1666142 · retained source version 1:2013-11-21:current:bfdf62acd042caae469b908236de50e12556640eee364827afa9610e71e6a896 ↗Source checked August 12, 2026
- PubMed record PMID 17078783 · retained source version 1:2016-11-24:current:fbb0f5b07890ba93a789adcee12683372efec2c912c8ccb000b271177e9dbcf7 ↗Source checked August 12, 2026
- PubMed record PMID 17131701 · retained source version 1:2016-11-24:current:98e6c25a5d7c64eccf87fa0e0ee2b23f4a5f79eb2628b64413d9f42cde329fe7 ↗Source checked August 12, 2026
- PubMed record PMID 17152723 · retained source version 1:2016-10-21:current:ccb8d9862a00e234963fc1b9d7e12d44803c621cdf34089942208f476b630a97 ↗Source checked August 12, 2026
- PubMed record PMID 17152724 · retained source version 1:2016-10-21:current:03a1de59f5a7840e0a0c5c3bf622e31effd2a70df7bfd27722e5f9c3fa476501 ↗Source checked August 12, 2026
- PubMed record PMID 17157748 · retained source version 1:2016-11-24:current:ab97d211c9ffae5ed79b64b9b8e08789f6e311334d754233f5b094530488f4b6 ↗Source checked August 12, 2026
- PubMed record PMID 17209456 · retained source version 1:2013-11-21:current:f66fe17cc52032ab6b7afa41a7113445635a94be453303bede57667a5dcf21e9 ↗Source checked August 12, 2026
- PubMed record PMID 17217245 · retained source version 1:2016-10-20:current:2936eeb01ead31286d4bf88f6f9b5948f55b041c0b88d78e2d66ccf5cf74155e ↗Source checked August 12, 2026
- PubMed record PMID 17310258 · retained source version 1:2016-11-24:current:243bc36efd00b98c5f6d0601b1477f1e2748069bd165b1f42de346840aee72c2 ↗Source checked August 12, 2026
- PubMed record PMID 1748007 · retained source version 1:2013-11-21:current:37077a498ef2dba1e03533b0ec30747cde62fafdd391f228b08024a66b20939f ↗Source checked August 12, 2026
- PubMed record PMID 17571443 · retained source version 1:2026-01-28:current:c464a5a138fc8cfd8edae6fcc473223b00cf2950436e88ae44f381eaa4f9dd26 ↗Source checked August 12, 2026
- PubMed record PMID 17694454 · retained source version 1:2017-11-16:current:849f112069247589f0c8da4c7828f40ab398f2fa42a9335751a70de1b79439f6 ↗Source checked August 12, 2026
- PubMed record PMID 17879973 · retained source version 1:2013-11-25:current:020c1683fd88782e25346f4adef25cff43df71ff86d00b1c0b49868f044ba496 ↗Source checked August 12, 2026
- PubMed record PMID 17955038 · retained source version 1:2007-12-17:current:3ed6b342d4a7372cfd69927f147952fe7e139c3a3437179d01572b662e8ca5ba ↗Source checked August 12, 2026
- PubMed record PMID 17963128 · retained source version 1:2016-11-24:current:a7a319285ce87a0ddda2350791f62518f2a00c02fa92fe24aefd348ddf88407e ↗Source checked August 12, 2026
- PubMed record PMID 1835275 · retained source version 1:2013-11-21:current:4109deb7aeb5b8ed310cc68b0be576988ff4b237aa162c475f9c91c012c98bbd ↗Source checked August 12, 2026
- PubMed record PMID 18366507 · retained source version 1:2016-11-24:current:f096fa6d33f2998979dacc52a457c91c451998bb88b2e361bd9178eec4d5b9eb ↗Source checked August 12, 2026
- PubMed record PMID 18366508 · retained source version 1:2016-11-24:current:50c5579c98a145daeb27bc0340df6a524062019bcee5120dee12892bec9a0b4d ↗Source checked August 12, 2026
- PubMed record PMID 18431004 · retained source version 1:2008-04-23:current:8be3427b1dd271352506986d52063951f313cce6c5670933191c4e43082f2bdf ↗Source checked August 12, 2026
- PubMed record PMID 18488900 · retained source version 1:2008-05-20:current:dd14954d5aadc0ec71f89ac87a6e7f0356f7c9900f8f7473b1e4bdfa2c348467 ↗Source checked August 12, 2026
- PubMed record PMID 18594781 · retained source version 1:2017-11-16:current:f077c97a9a7947f0b0176e500fbf625315dd3c37a0548c02a10a950a974b3c67 ↗Source checked August 12, 2026
- PubMed record PMID 18623910 · retained source version 1:2008-07-14:current:2069cdf08cfb078f426a3a223e33f68a4e8007fe7402c8416e4c2f9598fd25e6 ↗Source checked August 12, 2026
- PubMed record PMID 18756821 · retained source version 1:2008-09-01:current:0efcd984533b79364edb26597341d9d4ba931c92c340a312c77151ccc6f02993 ↗Source checked August 12, 2026
- PubMed record PMID 19098860 · retained source version 1:2017-11-16:current:a330b60deb32490aa79d56c9e3ba28d79a9aa810825636ac25cd3c632bc7aa3f ↗Source checked August 12, 2026
- PubMed record PMID 19243281 · retained source version 1:2019-09-17:current:95dbf12c2cde9bd6bc44b1f19832f09ac8d9bc9ece6ef4f37cef32cc8ee3989d ↗Source checked August 12, 2026
- PubMed record PMID 1941784 · retained source version 1:2013-11-21:current:7cd9029c21bb3f35852a853257123ed8a9b9d472f32d2b6233cff650449e02ce ↗Source checked August 12, 2026
- PubMed record PMID 19441725 · retained source version 1:2009-05-15:current:9a8f1a6ef2cd565ab15861a33094e0f6412b26ee555cdcab6e2260d077234881 ↗Source checked August 12, 2026
- PubMed record PMID 19465062 · retained source version 1:2017-11-16:current:8742ebc7d9f07fa77bffd591d871181e90a019506bb4596761b57c22b61c1e0e ↗Source checked August 12, 2026
- PubMed record PMID 19706070 · retained source version 1:2017-11-16:current:822e0ceaf89defd2e89610b7d7512da3e65843b757472e5cc2cf65e98c1b1bf6 ↗Source checked August 12, 2026
- PubMed record PMID 19732574 · retained source version 1:2013-11-25:current:d785f6a24bcf928d08ddd9454724c56590be1e7d503f6c4204224049ec658ce3 ↗Source checked August 12, 2026
- PubMed record PMID 1981209 · retained source version 1:2013-11-21:current:24775ba4f8092d5764ee78d870d33a8d2910d80e340703ef64ff4bdbb83a307c ↗Source checked August 12, 2026
- PubMed record PMID 19864727 · retained source version 1:2009-10-29:current:998c2af8dcb0728101d181d23927f50a37616496ca9a4020f586e6c9a95d4e14 ↗Source checked August 12, 2026
- PubMed record PMID 19864763 · retained source version 1:2009-10-29:current:e359d065e0c28855296414ef2a34f8a8eec9b5e6a4689845568d98919b40ab62 ↗Source checked August 12, 2026
- PubMed record PMID 19903499 · retained source version 1:2017-11-16:current:e08d8d4119e10d12467ab77a04f9878a1cd5f6d2bb1e45d5ba1447320da87ce3 ↗Source checked August 12, 2026
- PubMed record PMID 19931318 · retained source version 1:2017-11-16:current:21d11986ba32c4916f55c7c19ef2cb7e8ee502d80607f82195185f5834bab460 ↗Source checked August 12, 2026
- PubMed record PMID 20094043 · retained source version 1:2013-11-25:current:0014ede9f4f38993b78a7a93020ab095c1c08cd174c96ab710e424a6d011796e ↗Source checked August 12, 2026
- PubMed record PMID 20105039 · retained source version 1:2013-11-25:current:1276daf94383381b1109536555a5dd0e1f9509697eb1903589c88dbbd5784c49 ↗Source checked August 12, 2026
- PubMed record PMID 20164472 · retained source version 1:2013-11-25:current:0163a25779d13fc172d135c7209813df01246ab3ae9c417e1ca7ae795d668446 ↗Source checked August 12, 2026
- PubMed record PMID 20190676 · retained source version 1:2017-11-16:current:72346d9e18ceb058dea9fe59f145b908fbe9ca9f7a370d31541c15fd21fd7d8e ↗Source checked August 12, 2026
- PubMed record PMID 20405731 · retained source version 1:2016-10-21:current:bb7f249398da1da1c770ea34e0c8186df9b6f146b48558deab0f74baf514c9c8 ↗Source checked August 12, 2026
- PubMed record PMID 20560145 · retained source version 1:2017-11-16:current:412bbb408baa7aa6bf6c1f0e5ded7d7042a4aea88fec7b61d748e7b5e3ae7c0e ↗Source checked August 12, 2026
- PubMed record PMID 20610447 · retained source version 1:2012-02-09:current:8fa44394872de62bf52a390b1374fd33b0faaa9d6fff3def0fec62b1b9ed189f ↗Source checked August 12, 2026
- PubMed record PMID 20641226 · retained source version 1:2009-06-05:current:e4fb97211e4bb8fff7fb2f31cf76c3647f5b31a2a513bf8fb3f3a0029cb47aea ↗Source checked August 12, 2026
- PubMed record PMID 20641749 · retained source version 1:2007-11-07:current:81835ed70ec1d9d4df787cf579f405adf9a8ca852699f273f8a8a6f75ca91258 ↗Source checked August 12, 2026
- PubMed record PMID 2103273 · retained source version 1:2004-11-17:current:255a115bb2726ced65fc5a486a2e166e43cad17235ca8ef972c7c6dd7fae78e2 ↗Source checked August 12, 2026
- PubMed record PMID 2106145 · retained source version 1:2013-11-21:current:de1cf2eefc8cc09c40927413826d8e56a24d940d8f804dd237d962032d2fbb9e ↗Source checked August 12, 2026
- PubMed record PMID 21115997 · retained source version 1:2026-01-28:current:3e1e607998bf14b23017531243b6c6830aba4f3b50c22de213adbcb0d91f71f2 ↗Source checked August 12, 2026
- PubMed record PMID 2115128 · retained source version 1:2013-11-21:current:67e686dcd0d155eb6d200dddc2ffbdc83a7a2cb38a07c475bc5f5076df73496a ↗Source checked August 12, 2026
- PubMed record PMID 2119048 · retained source version 1:2013-11-21:current:9eced1134b788ca4ac5323af27164728555fa4c75c98c51b798225b979a55d07 ↗Source checked August 12, 2026
- PubMed record PMID 2120646 · retained source version 1:2013-11-21:current:00d72121458cc94b5220f4aafbd8cd04cf8ff3c40496b47b344e44cf1277a63c ↗Source checked August 12, 2026
- PubMed record PMID 21262293 · retained source version 1:2011-03-18:current:35d549d987ec7587214d9b04245b4ce6aca1fc004fce5cc8cadc532a6fc20955 ↗Source checked August 12, 2026
- PubMed record PMID 2153998 · retained source version 1:2004-11-17:current:7014a0a079bfbf3e5c5baf574f6d6b8070627eb0a3d28ed0f552f2caba218fb7 ↗Source checked August 12, 2026
- PubMed record PMID 21591600 · retained source version 1:2026-01-28:current:7ae3e5acb133cf05ce7e1e56cbb4eb013aa62039d53123eef58ebf1df62a41b2 ↗Source checked August 12, 2026
- PubMed record PMID 21695284 · retained source version 1:2018-12-01:current:51f750863a7ddf2026e109200de5c8faf23679945a04fe956a2e04855db8b52c ↗Source checked August 12, 2026
- PubMed record PMID 22050344 · retained source version 1:2017-11-16:current:bbbbcfcbe5d3029d9911e34a9a33d83c2e07e3368e93beb97d76a7179e85dda0 ↗Source checked August 12, 2026
- PubMed record PMID 22295573 · retained source version 1:2013-11-21:current:76591bd852c06e23407dc94f24bf6382317d95a989978dce1b625f18835ec6e9 ↗Source checked August 12, 2026
- PubMed record PMID 22840755 · retained source version 1:2013-02-01:current:e8fe61c4f69d9d2c50b3ffca7dea8590ab0b79431b358105c4947a0f96ffa79c ↗Source checked August 12, 2026
- PubMed record PMID 22874886 · retained source version 1:2013-05-13:current:338022f1735e0658a63e2208b1d7021f3aa568f5b3da3797c5517e67d4eeaede ↗Source checked August 12, 2026
- PubMed record PMID 22986396 · retained source version 1:2012-09-18:current:e565eb9336667316bbdeb008032951c81d8dc20bf40cf058a4536f5ba7f73b4e ↗Source checked August 12, 2026
- PubMed record PMID 22997980 · retained source version 1:2015-11-19:current:6823756083234c25c303d9e17ceb68dc1daf67e9d340f276d223651c936e5795 ↗Source checked August 12, 2026
- PubMed record PMID 23072114 · retained source version 1:2013-11-21:current:18b1274db8ffdd8df84fc4ecea7db5ba63b21d8a9ed8827ca211d9cdd744d0f2 ↗Source checked August 12, 2026
- PubMed record PMID 23140265 · retained source version 1:2013-01-01:current:a8fc75cef1afbd94a4859175e96dbcdf73a8ec5786e8b32ec2dab6739d9abb68 ↗Source checked August 12, 2026
- PubMed record PMID 23228417 · retained source version 1:2013-03-29:current:dd4f96d2a741825ed105db0505f69135e1bafeaafd322752909444937fd3831a ↗Source checked August 12, 2026
- PubMed record PMID 23275042 · retained source version 1:2013-05-06:current:031480758ac80cd82fbb1149a3a9a2d23b911b1e31fe4048bdc9ba4042b0b6ae ↗Source checked August 12, 2026
- PubMed record PMID 23591434 · retained source version 1:2013-04-17:current:2bfae6030f01429fd152f9b8cca6c332f2d16222898a7110f1a87c72e5c837eb ↗Source checked August 12, 2026
- PubMed record PMID 23780564 · retained source version 1:2013-06-21:current:f8d4ff210368b44a263e22500b402c9935f2891eb5daced15c8f8caf43907036 ↗Source checked August 12, 2026
- PubMed record PMID 23789763 · retained source version 1:2013-06-24:current:de4aed838180634167efefcf722b63cfc48031deb986e62de5e319aba59489b3 ↗Source checked August 12, 2026
- PubMed record PMID 23897194 · retained source version 1:2013-07-30:current:d69f7b3107e4132faee42393ef3ae3bb2aece8deddf47b0e1a538b4c811fbc32 ↗Source checked August 12, 2026
- PubMed record PMID 23925288 · retained source version 1:2013-08-08:current:1b29e8d745388855c58449b8452613529af0246dd9587dc7e3e0c1deba324f3c ↗Source checked August 12, 2026
- PubMed record PMID 23982227 · retained source version 1:2013-09-16:current:bf4a2733fa6453c65defec7b33c2918cc90ab2948deef3ed7e7bf86b52654b7d ↗Source checked August 12, 2026
- PubMed record PMID 24026625 · retained source version 1:2013-09-26:current:eab89c561e859280076ce8cf902b28a475cb03ed1febd28784c97e8f5ce09edc ↗Source checked August 12, 2026
- PubMed record PMID 24076523 · retained source version 1:2013-10-04:current:3520a8fd2ca43e30fb56cada0d9a8628954d29d9ba284ffffef769e74a77607b ↗Source checked August 12, 2026
- PubMed record PMID 2410765 · retained source version 1:2013-11-21:current:56413f88d72e9d7545b5562dd5ff95240a64619e7fec8608e8493745f80109f8 ↗Source checked August 12, 2026
- PubMed record PMID 2440061 · retained source version 1:2007-01-29:current:0623cbf2a845a962e30068bc041e952379acb10903175f42fb33c3926b2178cf ↗Source checked August 12, 2026
- PubMed record PMID 2474565 · retained source version 1:2013-11-21:current:4bfaaaff3894238decc894a4d23726db947a0f1490f738ea325c2a4b5a83de98 ↗Source checked August 12, 2026
- PubMed record PMID 25012990 · retained source version 1:2026-01-28:current:bf56af0c033df1459574b310479b1ac49d1a96141d62d151ad143dfe5b2ca87e ↗Source checked August 12, 2026
- PubMed record PMID 2503306 · retained source version 1:2004-11-17:current:7e4fe70dc6a7a7766eb8a4c3c6efe89a47f6a72dbc93f2fe64d26c2c53e9894f ↗Source checked August 12, 2026
- PubMed record PMID 25055456 · retained source version 1:2026-01-28:current:34e5122c527673bbe00a83a47d78d6b9e2871ac19212bc521695be2e971e5065 ↗Source checked August 12, 2026
- PubMed record PMID 25115916 · retained source version 1:2026-01-28:current:9125355d4df9e90eb556690f2e8c57356909bd602e068f9902c2c08d67038b88 ↗Source checked August 12, 2026
- PubMed record PMID 25130920 · retained source version 1:2026-01-28:current:9db17f73635e3805d423d65b68a3b870355124a61633d123944ec58277b844e1 ↗Source checked August 12, 2026
- PubMed record PMID 25402764 · retained source version 1:2017-11-16:current:9b918cb268491be56e4bc7e8b0901118e5fe27da3cd770551ec81bb5e9ee4794 ↗Source checked August 12, 2026
- PubMed record PMID 25494545 · retained source version 1:2026-01-28:current:a32615578cb7c605d258c0f672a10487d345b6e699a98bcadca214c4e8031ac6 ↗Source checked August 12, 2026
- PubMed record PMID 25535022 · retained source version 1:2019-12-10:current:e83ccae645938a2cababe40eaf143eac82488454407005010ac2111289ab566e ↗Source checked August 12, 2026
- PubMed record PMID 25607635 · retained source version 1:2018-12-02:current:dbda83ff6f858a70d8a2f09bbc0177cdba10f983a92dfc6cde77702d11206b4b ↗Source checked August 12, 2026
- PubMed record PMID 25607828 · retained source version 1:2018-12-02:current:6ef7dde1d9a215135b27358f1fd97f02d98dbbd2b6bad0c70168d08f897fde5b ↗Source checked August 12, 2026
- PubMed record PMID 25860029 · retained source version 1:2018-12-03:current:1de984e425f900e2c4271566b566be17452a978eeb8c00a7bc7513b0c5e6cd48 ↗Source checked August 12, 2026
- PubMed record PMID 25869809 · retained source version 1:2019-12-10:current:2d3fce659d63bdaaaead473a79c073e5ef818c68eda03597b6a12327b2167384 ↗Source checked August 12, 2026
- PubMed record PMID 25895899 · retained source version 1:2018-11-13:current:b6cec5e18781bbb2c6b95f3f05085532da2bbabce78450541749b035f38f6e28 ↗Source checked August 12, 2026
- PubMed record PMID 25998595 · retained source version 1:2015-05-22:current:f4ae2705406e2bb354dc1cbe880ede86ab6d16ba9f2538e25d130540f65b4c97 ↗Source checked August 12, 2026
- PubMed record PMID 26039935 · retained source version 1:2026-01-28:current:7198630cab0aef52da73de00999391fa3fdab6930bd4bdc6750c13d1802f42d5 ↗Source checked August 12, 2026
- PubMed record PMID 26132941 · retained source version 1:2018-11-13:current:a04a543e9049e177cda7593e432380c5d30e062b21d232d36f74edd35c4e5899 ↗Source checked August 12, 2026
- PubMed record PMID 26423184 · retained source version 1:2026-01-28:current:37b332c1191b188f872f33654c537b5761733da11a75923125a2d5aa3fd30c65 ↗Source checked August 12, 2026
- PubMed record PMID 26562265 · retained source version 1:2018-11-13:current:69af09569be9414cd1d2823309db844c6a44558553bbd187e1ebe14437004d2f ↗Source checked August 12, 2026
- PubMed record PMID 26979527 · retained source version 1:2017-11-16:current:db81c6d2ee3f46fcbd71d4bdfa5010ada99674b626ebde092e5d99cda8cd0ac3 ↗Source checked August 12, 2026
- PubMed record PMID 27200638 · retained source version 1:2016-05-21:current:bd5ab2899085891ac0b2608a9f1a93c3a47b08fdc665fb308e252cac04a77911 ↗Source checked August 12, 2026
- PubMed record PMID 27200644 · retained source version 1:2016-05-21:current:2640a2dfaaa3b0cda97c797716e7cc26f1f64cb047a649839ff13e896ecfd744 ↗Source checked August 12, 2026
- PubMed record PMID 27200645 · retained source version 1:2016-05-21:current:3a8a3e576869427c61398fe0d74d8c78522da6dd21b30fdfea475ff529ca7e21 ↗Source checked August 12, 2026
- PubMed record PMID 27200672 · retained source version 1:2016-05-21:current:17359823d1294c0736dcc9ba448e713d375c296331324d96b7c1571eeb3231d0 ↗Source checked August 12, 2026
- PubMed record PMID 27200673 · retained source version 1:2016-05-21:current:b3d695703333fa31ca7caa22cd885b0a997c57033d72897cb949e00e2b590bf7 ↗Source checked August 12, 2026
- PubMed record PMID 27200765 · retained source version 1:2016-05-21:current:dac7145405f6119187df46c7713bcce72f1001a392f4092ee6093bf09e012ff1 ↗Source checked August 12, 2026
- PubMed record PMID 27395059 · retained source version 1:2018-11-13:current:0864cbb65b5aa09a7953dc648e46e1f7da9ea35fbdc79f548473347bd4bf4eb7 ↗Source checked August 12, 2026
- PubMed record PMID 27612281 · retained source version 1:2018-10-15:current:31a69c68d513da23f45a1b7cb528dc2ac10be45e9c17f48c7464991c8a753953 ↗Source checked August 12, 2026
- PubMed record PMID 27748532 · retained source version 1:2018-10-15:current:aebb0330f8176c574ad1e8ce48095b2804a7cbce908e521fd8f822db07a52683 ↗Source checked August 12, 2026
- PubMed record PMID 27859635 · retained source version 1:2019-05-09:current:943903004fdb663734287534627869bd58ac109d2ef7d860e9bbbf63747e7b58 ↗Source checked August 12, 2026
- PubMed record PMID 27977473 · retained source version 1:2018-12-02:current:f76c4fa18d0c8ac0c024dd7b0bf3c491eab60cba3a8550597f75465b5b55e838 ↗Source checked August 12, 2026
- PubMed record PMID 28063031 · retained source version 1:2020-03-06:current:ea54e96246c3a0054220a9cd1b1a32542b9bd7864ed9d6142b1fedf25e61f8d8 ↗Source checked August 12, 2026
- PubMed record PMID 28189361 · retained source version 1:2019-03-18:current:9dc5a63edf62c13d835f33f2d712d5d2ed526a72f0b45795bf5dffd913e2ad50 ↗Source checked August 12, 2026
- PubMed record PMID 28255961 · retained source version 1:2026-01-27:current:a4c564c9d94778b438f63c41007ecd13c4855fde0452e34c19142a5327229951 ↗Source checked August 12, 2026
- PubMed record PMID 28389324 · retained source version 1:2018-12-02:current:eff92a3732c9e6c8384ca3980cdffa8eccd25a1853007b4a4fb659465b87c500 ↗Source checked August 12, 2026
- PubMed record PMID 28609423 · retained source version 1:2018-11-05:current:df73df22ca9c89ae082a8c3fa6acde71c259e3b1a56e4d2457a3d9d091baebe8 ↗Source checked August 12, 2026
- PubMed record PMID 28832410 · retained source version 1:2018-11-13:current:e68871cefd8ca9a3d9d0a9f67adf42bde243e3138315a48fafbfec416f88f6df ↗Source checked August 12, 2026
- PubMed record PMID 29251010 · retained source version 1:2018-12-02:current:9131fcc305226714dae4ffd962f752d673b0c7bbfad51f9b926a46b2b75fc74f ↗Source checked August 12, 2026
- PubMed record PMID 29260289 · retained source version 1:2019-02-25:current:e15f996dfaa70bec31f7538732a4aa708d62ae47b1bd1082a2264ae0b547eff8 ↗Source checked August 12, 2026
- PubMed record PMID 29276262 · retained source version 1:2019-11-20:current:d198c60f7293f27729ccfa3a9702752ab3f85cf3901b6b695ce9420eed3da260 ↗Source checked August 12, 2026
- PubMed record PMID 2952663 · retained source version 1:2004-11-17:current:48ed397bdb1b42cce1a2a2bb40e2c3adf8215823a53f03765d01efba3a0aba4e ↗Source checked August 12, 2026
- PubMed record PMID 29536610 · retained source version 1:2018-12-11:current:ac2bbf0a60a92f2a1e0d373fcb7db9f9e7c91ae06a7081348eb8d8a095d4f13a ↗Source checked August 12, 2026
- PubMed record PMID 2972904 · retained source version 1:2004-11-17:current:dd4af6c2b6f1215b2ac92ef52002fec06b32d98261ea8e91c73bfb0b539a0df7 ↗Source checked August 12, 2026
- PubMed record PMID 29800372 · retained source version 1:2019-03-26:current:63fe3648ae020853b832f62085ebc73fc7835d8516ec9f645a80afed71e1e8d0 ↗Source checked August 12, 2026
- PubMed record PMID 29852875 · retained source version 1:2019-01-03:current:eed713356b99de19f887a11fa7088687cbe9abc2062712b0c08eb1298e3d5a3a ↗Source checked August 12, 2026
- PubMed record PMID 2985414 · retained source version 1:2004-11-17:current:49b50fbfd885f1bd2349bba77a06e5a27b08ef32647117171877554bf51234b8 ↗Source checked August 12, 2026
- PubMed record PMID 29910025 · retained source version 1:2019-02-21:current:3aa8e573e3b738b170b9202952ecd40a89e452a5ea7933d9eb9ebf9144543976 ↗Source checked August 12, 2026
- PubMed record PMID 29911694 · retained source version 1:2018-08-23:current:4502810d9f62222a0efe0bb14fa28dacea35273b20c782e8f3be45b94331e2fa ↗Source checked August 12, 2026
- PubMed record PMID 29986520 · retained source version 1:2019-04-24:current:2fe79350e727bb3bb6abf0e3354f8f096e34b108ddda278e8bfe3a11d2ba32a4 ↗Source checked August 12, 2026
- PubMed record PMID 30277094 · retained source version 1:2020-04-27:current:1f13c9454c5c99da0cc7c25c80bc529cfa7bc8961920aaa303cbef0816c5002d ↗Source checked August 12, 2026